drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00002 | DB00448 | 1,284 | 1,215 | [
"DDInter344",
"DDInter1022"
] | Cetuximab | Lansoprazole | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells and EGFR overexpression has been linked to more advanced disease and poor prognosis. EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. Approved by the FDA in February 2004 under the brand name | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Moderate | 1 | [
[
[
1284,
24,
1215
]
],
[
[
1284,
24,
379
],
[
379,
1,
1215
]
],
[
[
1284,
24,
589
],
[
589,
63,
1215
]
],
[
[
1284,
24,
379
],
[
379,
40,
660
],
[
660,
1,
1215
]
],
[
[
1284,
24,
660
],
[
660,
1,
379
],
[
379,
1,
1215
]
],
[
[
1284,
24,
60
],
[
60,
6,
6017
],
[
6017,
45,
1215
]
],
[
[
1284,
24,
589
],
[
589,
24,
379
],
[
379,
1,
1215
]
],
[
[
1284,
24,
101
],
[
101,
23,
256
],
[
256,
62,
1215
]
],
[
[
1284,
24,
60
],
[
60,
21,
28882
],
[
28882,
60,
1215
]
],
[
[
1284,
24,
589
],
[
589,
63,
837
],
[
837,
1,
1215
]
]
] | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
]
] | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Lansoprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Lansoprazole (Compound) |
DB00467 | DB09481 | 1,467 | 460 | [
"DDInter644",
"DDInter1113"
] | Enoxacin | Magnesium carbonate | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1467,
24,
460
]
],
[
[
1467,
23,
752
],
[
752,
23,
460
]
],
[
[
1467,
1,
872
],
[
872,
24,
460
]
],
[
[
1467,
24,
853
],
[
853,
24,
460
]
],
[
[
1467,
64,
245
],
[
245,
24,
460
]
],
[
[
1467,
25,
959
],
[
959,
24,
460
]
],
[
[
1467,
40,
739
],
[
739,
24,
460
]
],
[
[
1467,
24,
428
],
[
428,
63,
460
]
],
[
[
1467,
23,
752
],
[
752,
62,
1252
],
[
1252,
23,
460
]
],
[
[
1467,
23,
60
],
[
60,
23,
872
],
[
872,
24,
460
]
]
] | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
]
] | Enoxacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Enoxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Enoxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate |
DB00524 | DB00736 | 811 | 660 | [
"DDInter1199",
"DDInter676"
] | Metolazone | Esomeprazole | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including , , and , for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including , , , , and . Esomeprazole is the s-isomer of , which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as , without any significant differences between the two compounds _in vitro_. Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists longer than 24 hours.[FDA Label] PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients such as iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life. Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. Esomeprazole doses should be slowly lowered, or tapered, before discontinuing to prevent this rebound effect. | Moderate | 1 | [
[
[
811,
24,
660
]
],
[
[
811,
63,
1215
],
[
1215,
40,
660
]
],
[
[
811,
24,
379
],
[
379,
40,
660
]
],
[
[
811,
63,
837
],
[
837,
1,
660
]
],
[
[
811,
21,
28785
],
[
28785,
60,
660
]
],
[
[
811,
63,
245
],
[
245,
23,
660
]
],
[
[
811,
24,
959
],
[
959,
62,
660
]
],
[
[
811,
1,
359
],
[
359,
63,
660
]
],
[
[
811,
24,
1287
],
[
1287,
24,
660
]
],
[
[
811,
23,
126
],
[
126,
24,
660
]
]
] | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Muscle spasms"
],
[
"Muscle spasms",
"{u} (Side Effect) is caused by {v} (Compound)",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
]
] | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound)
Metolazone (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Esomeprazole (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Metolazone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole |
DB00992 | DB01021 | 842 | 674 | [
"DDInter1182",
"DDInter1861"
] | Methyl aminolevulinate (topical) | Trichlormethiazide | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
842,
24,
674
]
],
[
[
842,
63,
1014
],
[
1014,
40,
674
]
],
[
[
842,
24,
178
],
[
178,
1,
674
]
],
[
[
842,
63,
1274
],
[
1274,
24,
674
]
],
[
[
842,
24,
848
],
[
848,
63,
674
]
],
[
[
842,
63,
1014
],
[
1014,
40,
178
],
[
178,
1,
674
]
],
[
[
842,
24,
178
],
[
178,
1,
1014
],
[
1014,
40,
674
]
],
[
[
842,
63,
359
],
[
359,
40,
1014
],
[
1014,
40,
674
]
],
[
[
842,
63,
1274
],
[
1274,
63,
1014
],
[
1014,
40,
674
]
],
[
[
842,
24,
848
],
[
848,
63,
1014
],
[
1014,
40,
674
]
]
] | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
]
]
] | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Polythiazide (Compound) and Polythiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound) |
DB00741 | DB01162 | 167 | 195 | [
"DDInter885",
"DDInter1767"
] | Hydrocortisone | Terazosin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Moderate | 1 | [
[
[
167,
24,
195
]
],
[
[
167,
63,
1205
],
[
1205,
40,
195
]
],
[
[
167,
6,
4973
],
[
4973,
45,
195
]
],
[
[
167,
21,
28882
],
[
28882,
60,
195
]
],
[
[
167,
40,
870
],
[
870,
24,
195
]
],
[
[
167,
1,
1220
],
[
1220,
63,
195
]
],
[
[
167,
24,
549
],
[
549,
63,
195
]
],
[
[
167,
1,
1486
],
[
1486,
24,
195
]
],
[
[
167,
25,
593
],
[
593,
24,
195
]
],
[
[
167,
63,
1648
],
[
1648,
24,
195
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[
"Prazosin",
"{u} (Compound) resembles {v} (Compound)",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Terazosin (Compound)
Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Terazosin (Compound)
Hydrocortisone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Terazosin (Compound)
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Terazosin
Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Terazosin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Terazosin
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Terazosin
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Terazosin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Terazosin |
DB00562 | DB00986 | 1,014 | 1,192 | [
"DDInter188",
"DDInter834"
] | Benzthiazide | Glycopyrronium | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopyrronium was originally granted FDA approval on 11 August 1961. | Minor | 0 | [
[
[
1014,
23,
1192
]
],
[
[
1014,
23,
1511
],
[
1511,
63,
1192
]
],
[
[
1014,
23,
262
],
[
262,
24,
1192
]
],
[
[
1014,
40,
504
],
[
504,
62,
1192
]
],
[
[
1014,
1,
811
],
[
811,
23,
1192
]
],
[
[
1014,
63,
475
],
[
475,
24,
1192
]
],
[
[
1014,
24,
849
],
[
849,
63,
1192
]
],
[
[
1014,
62,
19
],
[
19,
24,
1192
]
],
[
[
1014,
62,
352
],
[
352,
35,
1192
]
],
[
[
1014,
23,
1511
],
[
1511,
63,
262
],
[
262,
24,
1192
]
]
] | [
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
]
] | Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Trospium and Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium |
DB08899 | DB11853 | 129 | 230 | [
"DDInter649",
"DDInter1577"
] | Enzalutamide | Relugolix | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. | Minor | 0 | [
[
[
129,
23,
230
]
],
[
[
129,
62,
112
],
[
112,
23,
230
]
],
[
[
129,
63,
1101
],
[
1101,
23,
230
]
],
[
[
129,
25,
1476
],
[
1476,
62,
230
]
],
[
[
129,
24,
1040
],
[
1040,
23,
230
]
],
[
[
129,
63,
480
],
[
480,
24,
230
]
],
[
[
129,
24,
1662
],
[
1662,
24,
230
]
],
[
[
129,
25,
1456
],
[
1456,
24,
230
]
],
[
[
129,
64,
1213
],
[
1213,
24,
230
]
],
[
[
129,
25,
1017
],
[
1017,
63,
230
]
]
] | [
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
]
] | Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Enzalutamide may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Enzalutamide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Enzalutamide may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix |
DB00356 | DB01075 | 1,315 | 1,376 | [
"DDInter366",
"DDInter569"
] | Chlorzoxazone | Diphenhydramine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
1315,
24,
1376
]
],
[
[
1315,
24,
649
],
[
649,
63,
1376
]
],
[
[
1315,
24,
128
],
[
128,
24,
1376
]
],
[
[
1315,
6,
12523
],
[
12523,
45,
1376
]
],
[
[
1315,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
1315,
63,
701
],
[
701,
24,
1376
]
],
[
[
1315,
64,
475
],
[
475,
24,
1376
]
],
[
[
1315,
24,
272
],
[
272,
74,
1376
]
],
[
[
1315,
24,
662
],
[
662,
35,
1376
]
],
[
[
1315,
24,
649
],
[
649,
40,
11
],
[
11,
1,
1376
]
]
] | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
]
]
] | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Diphenhydramine (Compound)
Chlorzoxazone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Diphenhydramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Toremifene (Compound) and Toremifene (Compound) resembles Diphenhydramine (Compound) |
DB06448 | DB06603 | 171 | 39 | [
"DDInter1087",
"DDInter1387"
] | Lonafarnib | Panobinostat | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
171,
25,
39
]
],
[
[
171,
63,
112
],
[
112,
23,
39
]
],
[
[
171,
24,
1094
],
[
1094,
63,
39
]
],
[
[
171,
64,
455
],
[
455,
24,
39
]
],
[
[
171,
63,
869
],
[
869,
24,
39
]
],
[
[
171,
25,
578
],
[
578,
63,
39
]
],
[
[
171,
25,
594
],
[
594,
64,
39
]
],
[
[
171,
63,
1181
],
[
1181,
25,
39
]
],
[
[
171,
25,
1491
],
[
1491,
25,
39
]
],
[
[
171,
64,
477
],
[
477,
25,
39
]
]
] | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Lonafarnib may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Lonafarnib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Lonafarnib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Panobinostat
Lonafarnib may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Panobinostat
Lonafarnib may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Panobinostat |
DB00557 | DB01619 | 252 | 830 | [
"DDInter895",
"DDInter1441"
] | Hydroxyzine | Phenindamine | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. | Moderate | 1 | [
[
[
252,
24,
830
]
],
[
[
252,
24,
537
],
[
537,
40,
830
]
],
[
[
252,
40,
465
],
[
465,
1,
830
]
],
[
[
252,
63,
13
],
[
13,
24,
830
]
],
[
[
252,
24,
104
],
[
104,
1,
830
]
],
[
[
252,
6,
10104
],
[
10104,
45,
830
]
],
[
[
252,
23,
771
],
[
771,
62,
830
]
],
[
[
252,
24,
662
],
[
662,
24,
830
]
],
[
[
252,
24,
412
],
[
412,
63,
830
]
],
[
[
252,
74,
701
],
[
701,
24,
830
]
]
] | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorcyclizine"
],
[
"Chlorcyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
]
] | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Hydroxyzine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Phenindamine (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Phenindamine (Compound)
Hydroxyzine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Phenindamine (Compound)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenindamine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Hydroxyzine (Compound) resembles Clemastine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine |
DB10989 | DB14762 | 496 | 994 | [
"DDInter858",
"DDInter1602"
] | Hepatitis A Vaccine | Risankizumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis. | Moderate | 1 | [
[
[
496,
24,
994
]
],
[
[
496,
63,
4
],
[
4,
24,
994
]
],
[
[
496,
24,
270
],
[
270,
24,
994
]
],
[
[
496,
24,
676
],
[
676,
64,
994
]
],
[
[
496,
63,
1510
],
[
1510,
25,
994
]
],
[
[
496,
24,
1259
],
[
1259,
25,
994
]
],
[
[
496,
63,
4
],
[
4,
63,
58
],
[
58,
24,
994
]
],
[
[
496,
63,
58
],
[
58,
23,
1114
],
[
1114,
23,
994
]
],
[
[
496,
24,
270
],
[
270,
62,
1114
],
[
1114,
23,
994
]
],
[
[
496,
63,
147
],
[
147,
63,
1461
],
[
1461,
23,
994
]
]
] | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
]
] | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Risankizumab |
DB00477 | DB09039 | 216 | 1,670 | [
"DDInter363",
"DDInter629"
] | Chlorpromazine | Eliglustat | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Moderate | 1 | [
[
[
216,
24,
1670
]
],
[
[
216,
40,
1164
],
[
1164,
24,
1670
]
],
[
[
216,
63,
322
],
[
322,
24,
1670
]
],
[
[
216,
35,
272
],
[
272,
24,
1670
]
],
[
[
216,
25,
478
],
[
478,
24,
1670
]
],
[
[
216,
24,
918
],
[
918,
24,
1670
]
],
[
[
216,
1,
1237
],
[
1237,
24,
1670
]
],
[
[
216,
24,
124
],
[
124,
63,
1670
]
],
[
[
216,
25,
982
],
[
982,
63,
1670
]
],
[
[
216,
24,
1045
],
[
1045,
64,
1670
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
],
[
"Dacomitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
]
] | Chlorpromazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine (Compound) resembles Chlorpheniramine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib and Dacomitinib may lead to a major life threatening interaction when taken with Eliglustat |
DB01136 | DB08881 | 772 | 868 | [
"DDInter305",
"DDInter1925"
] | Carvedilol | Vemurafenib | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
772,
24,
868
]
],
[
[
772,
6,
8374
],
[
8374,
45,
868
]
],
[
[
772,
7,
1986
],
[
1986,
57,
868
]
],
[
[
772,
18,
16974
],
[
16974,
57,
868
]
],
[
[
772,
21,
29106
],
[
29106,
60,
868
]
],
[
[
772,
63,
608
],
[
608,
23,
868
]
],
[
[
772,
23,
578
],
[
578,
24,
868
]
],
[
[
772,
64,
480
],
[
480,
24,
868
]
],
[
[
772,
24,
760
],
[
760,
63,
868
]
],
[
[
772,
23,
286
],
[
286,
63,
868
]
]
] | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} (Compound) downregulates {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} (Compound) causes {v} (Side Effect)",
"Myalgia"
],
[
"Myalgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Carvedilol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Carvedilol (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is downregulated by Vemurafenib (Compound)
Carvedilol (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Vemurafenib (Compound)
Carvedilol (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Carvedilol may lead to a major life threatening interaction when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB06782 | DB09146 | 1,575 | 489 | [
"DDInter563",
"DDInter978"
] | Dimercaprol | Iron sucrose | Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. | Major | 2 | [
[
[
1575,
25,
489
]
],
[
[
1575,
25,
260
],
[
260,
63,
489
]
],
[
[
1575,
64,
1596
],
[
1596,
24,
489
]
],
[
[
1575,
25,
260
],
[
260,
63,
1152
],
[
1152,
24,
489
]
],
[
[
1575,
64,
1596
],
[
1596,
24,
943
],
[
943,
63,
489
]
],
[
[
1575,
21,
29635
],
[
29635,
60,
597
],
[
597,
24,
489
]
],
[
[
1575,
25,
428
],
[
428,
63,
943
],
[
943,
63,
489
]
],
[
[
1575,
64,
1596
],
[
1596,
24,
320
],
[
320,
24,
489
]
],
[
[
1575,
64,
1596
],
[
1596,
63,
1152
],
[
1152,
24,
489
]
],
[
[
1575,
25,
428
],
[
428,
24,
821
],
[
821,
63,
489
]
]
] | [
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous sulfate anhydrous"
],
[
"Ferrous sulfate anhydrous",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous sulfate anhydrous"
],
[
"Ferrous sulfate anhydrous",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} (Compound) causes {v} (Side Effect)",
"Burning sensation"
],
[
"Burning sensation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
],
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium chloride Ga-67"
],
[
"Gallium chloride Ga-67",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
]
] | Dimercaprol may lead to a major life threatening interaction when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol (Compound) causes Burning sensation (Side Effect) and Burning sensation (Side Effect) is caused by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine and Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Dimercaprol may lead to a major life threatening interaction when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Gallium chloride Ga-67 and Gallium chloride Ga-67 may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose |
DB00515 | DB12674 | 589 | 975 | [
"DDInter387",
"DDInter1105"
] | Cisplatin | Lurbinectedin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials. | Moderate | 1 | [
[
[
589,
24,
975
]
],
[
[
589,
24,
1488
],
[
1488,
24,
975
]
],
[
[
589,
63,
482
],
[
482,
24,
975
]
],
[
[
589,
64,
1648
],
[
1648,
24,
975
]
],
[
[
589,
25,
869
],
[
869,
24,
975
]
],
[
[
589,
25,
1259
],
[
1259,
25,
975
]
],
[
[
589,
25,
676
],
[
676,
64,
975
]
],
[
[
589,
64,
1064
],
[
1064,
25,
975
]
],
[
[
589,
24,
1419
],
[
1419,
25,
975
]
],
[
[
589,
63,
597
],
[
597,
25,
975
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cisplatin may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cisplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Cisplatin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Lurbinectedin
Cisplatin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Lurbinectedin
Cisplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Lurbinectedin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Lurbinectedin |
DB00554 | DB05773 | 1,027 | 1,047 | [
"DDInter1478",
"DDInter1848"
] | Piroxicam | Trastuzumab emtansine | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. | Moderate | 1 | [
[
[
1027,
24,
1047
]
],
[
[
1027,
24,
848
],
[
848,
24,
1047
]
],
[
[
1027,
24,
1613
],
[
1613,
63,
1047
]
],
[
[
1027,
63,
912
],
[
912,
24,
1047
]
],
[
[
1027,
40,
1171
],
[
1171,
24,
1047
]
],
[
[
1027,
25,
663
],
[
663,
24,
1047
]
],
[
[
1027,
63,
1018
],
[
1018,
25,
1047
]
],
[
[
1027,
25,
1409
],
[
1409,
64,
1047
]
],
[
[
1027,
24,
1347
],
[
1347,
25,
1047
]
],
[
[
1027,
24,
936
],
[
936,
64,
1047
]
]
] | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} (Compound) resembles {v} (Compound)",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
]
] | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Piroxicam (Compound) resembles Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Piroxicam may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Piroxicam may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor and Cangrelor may lead to a major life threatening interaction when taken with Trastuzumab emtansine |
DB00574 | DB00991 | 121 | 97 | [
"DDInter717",
"DDInter1358"
] | Fenfluramine | Oxaprozin | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
121,
24,
97
]
],
[
[
121,
25,
939
],
[
939,
40,
97
]
],
[
[
121,
24,
1274
],
[
1274,
24,
97
]
],
[
[
121,
63,
576
],
[
576,
1,
97
]
],
[
[
121,
24,
998
],
[
998,
1,
97
]
],
[
[
121,
24,
936
],
[
936,
63,
97
]
],
[
[
121,
63,
582
],
[
582,
24,
97
]
],
[
[
121,
25,
1039
],
[
1039,
63,
97
]
],
[
[
121,
24,
1213
],
[
1213,
64,
97
]
],
[
[
121,
63,
834
],
[
834,
25,
97
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
]
] | Fenfluramine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Oxaprozin (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Oxaprozin (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Oxaprozin (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dex
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Oxaprozin
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Oxaprozin |
DB00563 | DB08886 | 663 | 637 | [
"DDInter1174",
"DDInter126"
] | Methotrexate | Asparaginase Erwinia chrysanthemi | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
663,
24,
637
]
],
[
[
663,
64,
640
],
[
640,
24,
637
]
],
[
[
663,
24,
392
],
[
392,
24,
637
]
],
[
[
663,
63,
491
],
[
491,
24,
637
]
],
[
[
663,
24,
250
],
[
250,
63,
637
]
],
[
[
663,
25,
1479
],
[
1479,
24,
637
]
],
[
[
663,
23,
328
],
[
328,
24,
637
]
],
[
[
663,
25,
1510
],
[
1510,
25,
637
]
],
[
[
663,
63,
1101
],
[
1101,
25,
637
]
],
[
[
663,
64,
640
],
[
640,
25,
1517
],
[
1517,
24,
637
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Methotrexate may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Methotrexate may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00682 | DB14975 | 126 | 988 | [
"DDInter1951",
"DDInter1949"
] | Warfarin | Voxelotor | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424] | Moderate | 1 | [
[
[
126,
24,
988
]
],
[
[
126,
24,
222
],
[
222,
23,
988
]
],
[
[
126,
63,
251
],
[
251,
24,
988
]
],
[
[
126,
24,
985
],
[
985,
24,
988
]
],
[
[
126,
25,
792
],
[
792,
24,
988
]
],
[
[
126,
23,
477
],
[
477,
24,
988
]
],
[
[
126,
64,
1419
],
[
1419,
24,
988
]
],
[
[
126,
62,
467
],
[
467,
24,
988
]
],
[
[
126,
24,
913
],
[
913,
25,
988
]
],
[
[
126,
64,
600
],
[
600,
25,
988
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Voxelotor
Warfarin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Voxelotor |
DB00673 | DB00906 | 723 | 1,567 | [
"DDInter112",
"DDInter1801"
] | Aprepitant | Tiagabine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
723,
24,
1567
]
],
[
[
723,
6,
8374
],
[
8374,
45,
1567
]
],
[
[
723,
21,
28645
],
[
28645,
60,
1567
]
],
[
[
723,
63,
530
],
[
530,
24,
1567
]
],
[
[
723,
24,
283
],
[
283,
63,
1567
]
],
[
[
723,
25,
1476
],
[
1476,
63,
1567
]
],
[
[
723,
62,
1101
],
[
1101,
24,
1567
]
],
[
[
723,
24,
629
],
[
629,
24,
1567
]
],
[
[
723,
6,
8374
],
[
8374,
45,
530
],
[
530,
24,
1567
]
],
[
[
723,
21,
28645
],
[
28645,
60,
530
],
[
530,
24,
1567
]
]
] | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Aprepitant",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
]
] | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiagabine (Compound)
Aprepitant (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Tiagabine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Aprepitant (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine |
DB00108 | DB00480 | 1,066 | 1,668 | [
"DDInter1268",
"DDInter1035"
] | Natalizumab | Lenalidomide | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity. Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Major | 2 | [
[
[
1066,
25,
1668
]
],
[
[
1066,
25,
770
],
[
770,
40,
1668
]
],
[
[
1066,
64,
599
],
[
599,
24,
1668
]
],
[
[
1066,
25,
384
],
[
384,
63,
1668
]
],
[
[
1066,
24,
637
],
[
637,
63,
1668
]
],
[
[
1066,
25,
482
],
[
482,
24,
1668
]
],
[
[
1066,
25,
1011
],
[
1011,
64,
1668
]
],
[
[
1066,
64,
1057
],
[
1057,
25,
1668
]
],
[
[
1066,
25,
1064
],
[
1064,
25,
1668
]
],
[
[
1066,
25,
770
],
[
770,
40,
75
],
[
75,
1,
1668
]
]
] | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Pomalidomide"
],
[
"Pomalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Lenalidomide"
]
]
] | Natalizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Lenalidomide
Natalizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound) and Pomalidomide (Compound) resembles Lenalidomide (Compound) |
DB01059 | DB01254 | 956 | 1,213 | [
"DDInter1313",
"DDInter484"
] | Norfloxacin | Dasatinib | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
956,
24,
1213
]
],
[
[
956,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
956,
6,
3199
],
[
3199,
57,
1213
]
],
[
[
956,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
956,
62,
112
],
[
112,
23,
1213
]
],
[
[
956,
63,
1133
],
[
1133,
24,
1213
]
],
[
[
956,
24,
1619
],
[
1619,
63,
1213
]
],
[
[
956,
23,
973
],
[
973,
24,
1213
]
],
[
[
956,
62,
869
],
[
869,
24,
1213
]
],
[
[
956,
64,
891
],
[
891,
24,
1213
]
]
] | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] | Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Norfloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Dasatinib (Compound)
Norfloxacin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Norfloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00563 | DB00627 | 663 | 265 | [
"DDInter1174",
"DDInter1286"
] | Methotrexate | Niacin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Moderate | 1 | [
[
[
663,
24,
265
]
],
[
[
663,
6,
4390
],
[
4390,
45,
265
]
],
[
[
663,
21,
29169
],
[
29169,
60,
265
]
],
[
[
663,
25,
1479
],
[
1479,
62,
265
]
],
[
[
663,
63,
1647
],
[
1647,
24,
265
]
],
[
[
663,
24,
384
],
[
384,
63,
265
]
],
[
[
663,
25,
629
],
[
629,
63,
265
]
],
[
[
663,
25,
1510
],
[
1510,
64,
265
]
],
[
[
663,
24,
467
],
[
467,
64,
265
]
],
[
[
663,
6,
4390
],
[
4390,
45,
11404
],
[
11404,
1,
265
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC16A1"
],
[
"SLC16A1",
"{u} (Gene) is bound by {v} (Compound)",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Tinnitus"
],
[
"Tinnitus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niacin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC16A1"
],
[
"SLC16A1",
"{u} (Gene) is bound by {v} (Compound)",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} (Compound) resembles {v} (Compound)",
"Niacin"
]
]
] | Methotrexate (Compound) binds SLC16A1 (Gene) and SLC16A1 (Gene) is bound by Niacin (Compound)
Methotrexate (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Niacin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Niacin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Methotrexate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Methotrexate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Niacin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Niacin
Methotrexate (Compound) binds SLC16A1 (Gene) and SLC16A1 (Gene) is bound by Salicylic acid (Compound) and Salicylic acid (Compound) resembles Niacin (Compound) |
DB00736 | DB01066 | 660 | 1,462 | [
"DDInter676",
"DDInter316"
] | Esomeprazole | Cefditoren | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including,, and, for example.[A177271, F4498] Its efficacy is considered similar to other medications within the PPI class including,,,, and. Esomeprazole is the s-isomer of, which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as, without any significant differences between the two compounds _in vitro_. Esome | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
660,
24,
1462
]
],
[
[
660,
24,
665
],
[
665,
40,
1462
]
],
[
[
660,
40,
837
],
[
837,
24,
1462
]
],
[
[
660,
63,
126
],
[
126,
24,
1462
]
],
[
[
660,
1,
379
],
[
379,
63,
1462
]
],
[
[
660,
1,
1215
],
[
1215,
24,
1462
]
],
[
[
660,
24,
665
],
[
665,
40,
1403
],
[
1403,
40,
1462
]
],
[
[
660,
40,
837
],
[
837,
24,
665
],
[
665,
40,
1462
]
],
[
[
660,
63,
126
],
[
126,
24,
1403
],
[
1403,
40,
1462
]
],
[
[
660,
1,
379
],
[
379,
63,
665
],
[
665,
40,
1462
]
]
] | [
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
],
[
"Cefepime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
],
[
"Cefepime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
]
]
] | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefepime (Compound) and Cefepime (Compound) resembles Cefditoren (Compound)
Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Cefditoren (Compound)
Esomeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound) |
DB01254 | DB12001 | 1,213 | 564 | [
"DDInter484",
"DDInter7"
] | Dasatinib | Abemaciclib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. | Moderate | 1 | [
[
[
1213,
24,
564
]
],
[
[
1213,
63,
536
],
[
536,
24,
564
]
],
[
[
1213,
25,
868
],
[
868,
24,
564
]
],
[
[
1213,
24,
748
],
[
748,
24,
564
]
],
[
[
1213,
25,
982
],
[
982,
63,
564
]
],
[
[
1213,
24,
1017
],
[
1017,
63,
564
]
],
[
[
1213,
64,
1091
],
[
1091,
24,
564
]
],
[
[
1213,
25,
68
],
[
68,
64,
564
]
],
[
[
1213,
25,
1011
],
[
1011,
25,
564
]
],
[
[
1213,
64,
581
],
[
581,
25,
564
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
]
] | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Abemaciclib
Dasatinib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Abemaciclib |
DB00549 | DB06335 | 522 | 761 | [
"DDInter1955",
"DDInter1646"
] | Zafirlukast | Saxagliptin | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
522,
24,
761
]
],
[
[
522,
6,
8374
],
[
8374,
45,
761
]
],
[
[
522,
21,
29226
],
[
29226,
60,
761
]
],
[
[
522,
23,
307
],
[
307,
23,
761
]
],
[
[
522,
24,
1491
],
[
1491,
63,
761
]
],
[
[
522,
24,
478
],
[
478,
24,
761
]
],
[
[
522,
63,
1028
],
[
1028,
24,
761
]
],
[
[
522,
23,
222
],
[
222,
24,
761
]
],
[
[
522,
25,
171
],
[
171,
63,
761
]
],
[
[
522,
6,
8374
],
[
8374,
45,
307
],
[
307,
23,
761
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
]
] | Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Zafirlukast (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Saxagliptin (Compound)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Zafirlukast may lead to a major life threatening interaction when taken with Lonafarnib and Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin |
DB00860 | DB08912 | 891 | 1,040 | [
"DDInter1513",
"DDInter462"
] | Prednisolone | Dabrafenib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
891,
24,
1040
]
],
[
[
891,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
891,
18,
2642
],
[
2642,
46,
1040
]
],
[
[
891,
7,
3163
],
[
3163,
46,
1040
]
],
[
[
891,
18,
5416
],
[
5416,
57,
1040
]
],
[
[
891,
21,
28787
],
[
28787,
60,
1040
]
],
[
[
891,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
891,
24,
478
],
[
478,
24,
1040
]
],
[
[
891,
40,
870
],
[
870,
24,
1040
]
],
[
[
891,
63,
312
],
[
312,
24,
1040
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) downregulates {v} (Gene)",
"PAN2"
],
[
"PAN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) downregulates {v} (Gene)",
"KIF14"
],
[
"KIF14",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
]
] | Prednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Prednisolone (Compound) downregulates PAN2 (Gene) and PAN2 (Gene) is upregulated by Dabrafenib (Compound)
Prednisolone (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dabrafenib (Compound)
Prednisolone (Compound) downregulates KIF14 (Gene) and KIF14 (Gene) is downregulated by Dabrafenib (Compound)
Prednisolone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Dabrafenib (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib |
DB00191 | DB01221 | 73 | 1,190 | [
"DDInter1447",
"DDInter1007"
] | Phentermine | Ketamine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes. | Moderate | 1 | [
[
[
73,
24,
1190
]
],
[
[
73,
6,
6017
],
[
6017,
45,
1190
]
],
[
[
73,
21,
28787
],
[
28787,
60,
1190
]
],
[
[
73,
25,
222
],
[
222,
24,
1190
]
],
[
[
73,
35,
22
],
[
22,
63,
1190
]
],
[
[
73,
24,
1152
],
[
1152,
24,
1190
]
],
[
[
73,
25,
1629
],
[
1629,
63,
1190
]
],
[
[
73,
24,
591
],
[
591,
63,
1190
]
],
[
[
73,
6,
6017
],
[
6017,
45,
530
],
[
530,
24,
1190
]
],
[
[
73,
21,
28787
],
[
28787,
60,
1311
],
[
1311,
63,
1190
]
]
] | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
],
[
"Ioflupane I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
]
] | Phentermine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ketamine (Compound)
Phentermine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketamine (Compound)
Phentermine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine (Compound) resembles Ephedrine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 and Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Phentermine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ketamine |
DB01244 | DB14723 | 762 | 159 | [
"DDInter192",
"DDInter1026"
] | Bepridil | Larotrectinib | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
762,
24,
159
]
],
[
[
762,
23,
1135
],
[
1135,
23,
159
]
],
[
[
762,
64,
322
],
[
322,
24,
159
]
],
[
[
762,
24,
1446
],
[
1446,
24,
159
]
],
[
[
762,
25,
1619
],
[
1619,
24,
159
]
],
[
[
762,
63,
530
],
[
530,
24,
159
]
],
[
[
762,
40,
704
],
[
704,
24,
159
]
],
[
[
762,
25,
129
],
[
129,
25,
159
]
],
[
[
762,
24,
384
],
[
384,
25,
159
]
],
[
[
762,
64,
609
],
[
609,
25,
159
]
]
] | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
]
] | Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Bepridil may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bepridil may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bepridil (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Bepridil may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Larotrectinib
Bepridil may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Larotrectinib |
DB00574 | DB04932 | 121 | 1,564 | [
"DDInter717",
"DDInter491"
] | Fenfluramine | Defibrotide | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio. | Moderate | 1 | [
[
[
121,
24,
1564
]
],
[
[
121,
24,
914
],
[
914,
24,
1564
]
],
[
[
121,
25,
1039
],
[
1039,
24,
1564
]
],
[
[
121,
64,
1100
],
[
1100,
24,
1564
]
],
[
[
121,
63,
1027
],
[
1027,
24,
1564
]
],
[
[
121,
25,
41
],
[
41,
63,
1564
]
],
[
[
121,
63,
202
],
[
202,
25,
1564
]
],
[
[
121,
24,
279
],
[
279,
25,
1564
]
],
[
[
121,
24,
283
],
[
283,
64,
1564
]
],
[
[
121,
25,
39
],
[
39,
64,
1564
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ardeparin"
],
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
]
] | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dex
Fenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Defibrotide
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Defibrotide
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Defibrotide
Fenfluramine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Defibrotide |
DB00274 | DB01024 | 277 | 1,096 | [
"DDInter320",
"DDInter1252"
] | Cefmetazole | Mycophenolic acid | A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection. | Moderate | 1 | [
[
[
277,
24,
1096
]
],
[
[
277,
18,
7212
],
[
7212,
57,
1096
]
],
[
[
277,
1,
1124
],
[
1124,
63,
1096
]
],
[
[
277,
24,
597
],
[
597,
24,
1096
]
],
[
[
277,
24,
416
],
[
416,
63,
1096
]
],
[
[
277,
18,
7212
],
[
7212,
57,
955
],
[
955,
1,
1096
]
],
[
[
277,
1,
1124
],
[
1124,
1,
315
],
[
315,
63,
1096
]
],
[
[
277,
1,
1323
],
[
1323,
40,
1124
],
[
1124,
63,
1096
]
],
[
[
277,
24,
597
],
[
597,
24,
955
],
[
955,
1,
1096
]
],
[
[
277,
1,
1402
],
[
1402,
21,
28701
],
[
28701,
60,
1096
]
]
] | [
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) downregulates {v} (Gene)",
"HMG20B"
],
[
"HMG20B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
],
[
"Cefamandole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) downregulates {v} (Gene)",
"HMG20B"
],
[
"HMG20B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
],
[
"Cefamandole",
"{u} (Compound) resembles {v} (Compound)",
"Cefprozil"
],
[
"Cefprozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefonicid"
],
[
"Cefonicid",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
],
[
"Cefamandole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefotetan"
],
[
"Cefotetan",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mycophenolic acid"
]
]
] | Cefmetazole (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Mycophenolic acid (Compound)
Cefmetazole (Compound) resembles Cefamandole (Compound) and Cefamandole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Cefmetazole (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Mycophenolate mofetil (Compound) and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Cefmetazole (Compound) resembles Cefamandole (Compound) and Cefamandole (Compound) resembles Cefprozil (Compound) and Cefprozil may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Cefmetazole (Compound) resembles Cefonicid (Compound) and Cefonicid (Compound) resembles Cefamandole (Compound) and Cefamandole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Cefmetazole (Compound) resembles Cefotetan (Compound) and Cefotetan (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Mycophenolic acid (Compound) |
DB00434 | DB00924 | 13 | 1,405 | [
"DDInter459",
"DDInter454"
] | Cyproheptadine | Cyclobenzaprine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. | Moderate | 1 | [
[
[
13,
35,
1405
]
],
[
[
13,
24,
649
],
[
649,
63,
1405
]
],
[
[
13,
63,
1302
],
[
1302,
1,
1405
]
],
[
[
13,
24,
1236
],
[
1236,
1,
1405
]
],
[
[
13,
40,
114
],
[
114,
1,
1405
]
],
[
[
13,
74,
21
],
[
21,
1,
1405
]
],
[
[
13,
24,
1264
],
[
1264,
64,
1405
]
],
[
[
13,
6,
4228
],
[
4228,
45,
1405
]
],
[
[
13,
10,
11610
],
[
11610,
49,
1405
]
],
[
[
13,
21,
28826
],
[
28826,
60,
1405
]
]
] | [
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"HTR2A"
],
[
"HTR2A",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) palliates {v} (Disease)",
"migraine"
],
[
"migraine",
"{u} (Disease) is palliated by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclobenzaprine"
]
]
] | Cyproheptadine (Compound) resembles Cyclobenzaprine (Compound) and
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Cyclobenzaprine (Compound)
Cyproheptadine (Compound) resembles Nortriptyline (Compound) and Nortriptyline (Compound) resembles Cyclobenzaprine (Compound)
Cyproheptadine (Compound) resembles Amitriptyline (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Cyclobenzaprine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Cyproheptadine (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Cyclobenzaprine (Compound)
Cyproheptadine (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Cyclobenzaprine (Compound)
Cyproheptadine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Cyclobenzaprine (Compound) |
DB00741 | DB01432 | 167 | 857 | [
"DDInter885",
"DDInter368"
] | Hydrocortisone | Cholestyramine | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Moderate | 1 | [
[
[
167,
24,
857
]
],
[
[
167,
63,
1512
],
[
1512,
23,
857
]
],
[
[
167,
24,
1479
],
[
1479,
23,
857
]
],
[
[
167,
24,
1411
],
[
1411,
24,
857
]
],
[
[
167,
40,
870
],
[
870,
24,
857
]
],
[
[
167,
1,
1220
],
[
1220,
24,
857
]
],
[
[
167,
63,
126
],
[
126,
24,
857
]
],
[
[
167,
25,
1377
],
[
1377,
24,
857
]
],
[
[
167,
25,
1510
],
[
1510,
64,
857
]
],
[
[
167,
63,
1512
],
[
1512,
24,
1479
],
[
1479,
23,
857
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholestyramine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Hydrocortisone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Hydrocortisone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cholestyramine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine |
DB00281 | DB00532 | 608 | 208 | [
"DDInter1066",
"DDInter1152"
] | Lidocaine | Mephenytoin | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants. | Minor | 0 | [
[
[
608,
23,
208
]
],
[
[
608,
24,
908
],
[
908,
63,
208
]
],
[
[
608,
63,
1057
],
[
1057,
24,
208
]
],
[
[
608,
23,
1040
],
[
1040,
63,
208
]
],
[
[
608,
24,
1010
],
[
1010,
24,
208
]
],
[
[
608,
23,
1510
],
[
1510,
64,
208
]
],
[
[
608,
63,
600
],
[
600,
25,
208
]
],
[
[
608,
24,
908
],
[
908,
64,
168
],
[
168,
23,
208
]
],
[
[
608,
63,
1057
],
[
1057,
25,
168
],
[
168,
23,
208
]
],
[
[
608,
24,
259
],
[
259,
63,
168
],
[
168,
23,
208
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mephenytoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mephenytoin"
]
]
] | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Mephenytoin |
DB08880 | DB11569 | 1,510 | 1,093 | [
"DDInter1771",
"DDInter1003"
] | Teriflunomide | Ixekizumab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Major | 2 | [
[
[
1510,
25,
1093
]
],
[
[
1510,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
1510,
62,
1461
],
[
1461,
23,
1093
]
],
[
[
1510,
62,
608
],
[
608,
24,
1093
]
],
[
[
1510,
64,
66
],
[
66,
24,
1093
]
],
[
[
1510,
24,
496
],
[
496,
24,
1093
]
],
[
[
1510,
63,
303
],
[
303,
24,
1093
]
],
[
[
1510,
24,
1367
],
[
1367,
63,
1093
]
],
[
[
1510,
25,
975
],
[
975,
63,
1093
]
],
[
[
1510,
25,
713
],
[
713,
24,
1093
]
]
] | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
],
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
]
] | Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Teriflunomide may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab |
DB01320 | DB08907 | 651 | 1,344 | [
"DDInter783",
"DDInter280"
] | Fosphenytoin | Canagliflozin | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
651,
24,
1344
]
],
[
[
651,
6,
1829
],
[
1829,
45,
1344
]
],
[
[
651,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
651,
25,
1033
],
[
1033,
63,
1344
]
],
[
[
651,
63,
1486
],
[
1486,
24,
1344
]
],
[
[
651,
24,
850
],
[
850,
24,
1344
]
],
[
[
651,
24,
1296
],
[
1296,
63,
1344
]
],
[
[
651,
64,
168
],
[
168,
24,
1344
]
],
[
[
651,
25,
1491
],
[
1491,
24,
1344
]
],
[
[
651,
40,
362
],
[
362,
24,
1344
]
]
] | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkalaemia"
],
[
"Hyperkalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Fosphenytoin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Canagliflozin (Compound)
Fosphenytoin (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Fosphenytoin may lead to a major life threatening interaction when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Fosphenytoin (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB00363 | DB01075 | 695 | 1,376 | [
"DDInter419",
"DDInter569"
] | Clozapine | Diphenhydramine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
695,
24,
1376
]
],
[
[
695,
24,
649
],
[
649,
63,
1376
]
],
[
[
695,
25,
11
],
[
11,
1,
1376
]
],
[
[
695,
24,
128
],
[
128,
24,
1376
]
],
[
[
695,
24,
126
],
[
126,
1,
1376
]
],
[
[
695,
25,
888
],
[
888,
25,
1376
]
],
[
[
695,
6,
12523
],
[
12523,
45,
1376
]
],
[
[
695,
10,
11584
],
[
11584,
49,
1376
]
],
[
[
695,
1,
623
],
[
623,
63,
1376
]
],
[
[
695,
63,
701
],
[
701,
24,
1376
]
]
] | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} (Compound) palliates {v} (Disease)",
"schizophrenia"
],
[
"schizophrenia",
"{u} (Disease) is palliated by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
]
] | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clozapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Diphenhydramine (Compound)
Clozapine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine
Clozapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Diphenhydramine (Compound)
Clozapine (Compound) palliates schizophrenia (Disease) and schizophrenia (Disease) is palliated by Diphenhydramine (Compound)
Clozapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine |
DB00307 | DB14840 | 1,101 | 861 | [
"DDInter202",
"DDInter1601"
] | Bexarotene | Ripretinib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors. | Moderate | 1 | [
[
[
1101,
24,
861
]
],
[
[
1101,
24,
351
],
[
351,
24,
861
]
],
[
[
1101,
23,
353
],
[
353,
24,
861
]
],
[
[
1101,
25,
1476
],
[
1476,
24,
861
]
],
[
[
1101,
62,
1324
],
[
1324,
24,
861
]
],
[
[
1101,
64,
966
],
[
966,
24,
861
]
],
[
[
1101,
24,
384
],
[
384,
25,
861
]
],
[
[
1101,
23,
760
],
[
760,
25,
861
]
],
[
[
1101,
24,
351
],
[
351,
24,
214
],
[
214,
24,
861
]
],
[
[
1101,
24,
214
],
[
214,
63,
351
],
[
351,
24,
861
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
]
] | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may lead to a major life threatening interaction when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ripretinib
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Ripretinib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib |
DB00106 | DB01268 | 618 | 1,151 | [
"DDInter4",
"DDInter1731"
] | Abarelix | Sunitinib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
618,
24,
1151
]
],
[
[
618,
23,
1247
],
[
1247,
23,
1151
]
],
[
[
618,
24,
1148
],
[
1148,
24,
1151
]
],
[
[
618,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
618,
63,
317
],
[
317,
24,
1151
]
],
[
[
618,
25,
1327
],
[
1327,
25,
1151
]
],
[
[
618,
25,
982
],
[
982,
64,
1151
]
],
[
[
618,
24,
1487
],
[
1487,
64,
1151
]
],
[
[
618,
25,
1401
],
[
1401,
36,
1151
]
],
[
[
618,
23,
1247
],
[
1247,
6,
8374
],
[
8374,
45,
1151
]
]
] | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vasopressin"
],
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
]
] | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Vasopressin and Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Abarelix may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Sunitinib
Abarelix may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Sunitinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Sunitinib
Abarelix may lead to a major life threatening interaction when taken with Procainamide and Procainamide (Compound) resembles Sunitinib (Compound) and Procainamide may lead to a major life threatening interaction when taken with Sunitinib
Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound) |
DB04845 | DB06674 | 309 | 908 | [
"DDInter1001",
"DDInter837"
] | Ixabepilone | Golimumab | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. | Major | 2 | [
[
[
309,
25,
908
]
],
[
[
309,
63,
1461
],
[
1461,
23,
908
]
],
[
[
309,
63,
336
],
[
336,
24,
908
]
],
[
[
309,
24,
505
],
[
505,
63,
908
]
],
[
[
309,
24,
1136
],
[
1136,
24,
908
]
],
[
[
309,
63,
1220
],
[
1220,
25,
908
]
],
[
[
309,
25,
334
],
[
334,
64,
908
]
],
[
[
309,
24,
1683
],
[
1683,
25,
908
]
],
[
[
309,
64,
1377
],
[
1377,
25,
908
]
],
[
[
309,
24,
713
],
[
713,
64,
908
]
]
] | [
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
],
[
"Diiodohydroxyquinoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
]
] | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline and Diiodohydroxyquinoline may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Golimumab
Ixabepilone may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Golimumab
Ixabepilone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Golimumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Golimumab |
DB01234 | DB09068 | 1,220 | 1,427 | [
"DDInter513",
"DDInter1948"
] | Dexamethasone | Vortioxetine | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. | Moderate | 1 | [
[
[
1220,
24,
1427
]
],
[
[
1220,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
1220,
63,
1685
],
[
1685,
24,
1427
]
],
[
[
1220,
25,
1017
],
[
1017,
63,
1427
]
],
[
[
1220,
25,
1213
],
[
1213,
24,
1427
]
],
[
[
1220,
24,
129
],
[
129,
24,
1427
]
],
[
[
1220,
62,
1018
],
[
1018,
24,
1427
]
],
[
[
1220,
64,
1314
],
[
1314,
24,
1427
]
],
[
[
1220,
25,
497
],
[
497,
25,
1427
]
],
[
[
1220,
64,
593
],
[
593,
25,
1427
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
]
] | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may lead to a major life threatening interaction when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dexamethasone may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Vortioxetine
Dexamethasone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Vortioxetine |
DB01242 | DB12500 | 1,237 | 283 | [
"DDInter410",
"DDInter714"
] | Clomipramine | Fedratinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic ser | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1237,
24,
283
]
],
[
[
1237,
25,
351
],
[
351,
23,
283
]
],
[
[
1237,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1237,
24,
971
],
[
971,
24,
283
]
],
[
[
1237,
40,
216
],
[
216,
24,
283
]
],
[
[
1237,
25,
985
],
[
985,
24,
283
]
],
[
[
1237,
64,
1133
],
[
1133,
24,
283
]
],
[
[
1237,
1,
1216
],
[
1216,
24,
283
]
],
[
[
1237,
74,
1264
],
[
1264,
24,
283
]
],
[
[
1237,
63,
888
],
[
888,
25,
283
]
]
] | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Clomipramine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine (Compound) resembles Doxepin (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib |
DB00685 | DB11093 | 1,299 | 636 | [
"DDInter1887",
"DDInter273"
] | Trovafloxacin | Calcium citrate | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1299,
24,
636
]
],
[
[
1299,
1,
739
],
[
739,
24,
636
]
],
[
[
1299,
24,
115
],
[
115,
25,
636
]
],
[
[
1299,
1,
739
],
[
739,
40,
1176
],
[
1176,
24,
636
]
],
[
[
1299,
21,
28863
],
[
28863,
60,
819
],
[
819,
24,
636
]
],
[
[
1299,
24,
115
],
[
115,
62,
819
],
[
819,
24,
636
]
],
[
[
1299,
1,
739
],
[
739,
1,
1539
],
[
1539,
24,
636
]
],
[
[
1299,
24,
115
],
[
115,
63,
1572
],
[
1572,
24,
636
]
],
[
[
1299,
24,
115
],
[
115,
25,
1436
],
[
1436,
24,
636
]
],
[
[
1299,
1,
1467
],
[
1467,
24,
115
],
[
115,
25,
636
]
]
] | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Lightheadedness"
],
[
"Lightheadedness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium citrate"
]
]
] | Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate
Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate |
DB00637 | DB11601 | 1,557 | 1,270 | [
"DDInter128",
"DDInter1889"
] | Astemizole | Tuberculin purified protein derivative | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1557,
24,
1270
]
],
[
[
1557,
63,
1555
],
[
1555,
24,
1270
]
],
[
[
1557,
24,
1250
],
[
1250,
24,
1270
]
],
[
[
1557,
25,
1011
],
[
1011,
24,
1270
]
],
[
[
1557,
24,
1619
],
[
1619,
63,
1270
]
],
[
[
1557,
25,
351
],
[
351,
63,
1270
]
],
[
[
1557,
63,
1555
],
[
1555,
24,
350
],
[
350,
24,
1270
]
],
[
[
1557,
24,
1250
],
[
1250,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
1557,
63,
322
],
[
322,
64,
550
],
[
550,
24,
1270
]
],
[
[
1557,
25,
1011
],
[
1011,
25,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Astemizole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB05239 | DB09098 | 866 | 98 | [
"DDInter425",
"DDInter1700"
] | Cobimetinib | Somatrem | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
866,
24,
98
]
],
[
[
866,
63,
336
],
[
336,
24,
98
]
],
[
[
866,
24,
159
],
[
159,
63,
98
]
],
[
[
866,
64,
609
],
[
609,
24,
98
]
],
[
[
866,
25,
1580
],
[
1580,
63,
98
]
],
[
[
866,
25,
875
],
[
875,
24,
98
]
],
[
[
866,
24,
1374
],
[
1374,
24,
98
]
],
[
[
866,
63,
1101
],
[
1101,
25,
98
]
],
[
[
866,
63,
336
],
[
336,
24,
159
],
[
159,
63,
98
]
],
[
[
866,
63,
1671
],
[
1671,
62,
168
],
[
168,
23,
98
]
]
] | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
],
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
]
] | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may lead to a major life threatening interaction when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may lead to a major life threatening interaction when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00065 | DB00432 | 581 | 1,083 | [
"DDInter923",
"DDInter1868"
] | Infliximab | Trifluridine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2 . The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets incorporated into DNA of cancer cells following cell uptake to aberrate DNA function during cell replication . | Major | 2 | [
[
[
581,
25,
1083
]
],
[
[
581,
24,
1477
],
[
1477,
40,
1083
]
],
[
[
581,
25,
1238
],
[
1238,
1,
1083
]
],
[
[
581,
25,
139
],
[
139,
63,
1083
]
],
[
[
581,
24,
231
],
[
231,
1,
1083
]
],
[
[
581,
24,
1367
],
[
1367,
63,
1083
]
],
[
[
581,
24,
58
],
[
58,
24,
1083
]
],
[
[
581,
23,
1461
],
[
1461,
24,
1083
]
],
[
[
581,
64,
1184
],
[
1184,
24,
1083
]
],
[
[
581,
25,
695
],
[
695,
25,
1083
]
]
] | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} (Compound) resembles {v} (Compound)",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
],
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
]
]
] | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Trifluridine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin (Compound) resembles Trifluridine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine (Compound) resembles Trifluridine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Infliximab may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Trifluridine |
DB01142 | DB01238 | 1,264 | 673 | [
"DDInter593",
"DDInter118"
] | Doxepin | Aripiprazole | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Moderate | 1 | [
[
[
1264,
24,
673
]
],
[
[
1264,
25,
851
],
[
851,
1,
673
]
],
[
[
1264,
64,
827
],
[
827,
40,
673
]
],
[
[
1264,
63,
1630
],
[
1630,
1,
673
]
],
[
[
1264,
6,
3895
],
[
3895,
45,
673
]
],
[
[
1264,
21,
28792
],
[
28792,
60,
673
]
],
[
[
1264,
62,
112
],
[
112,
23,
673
]
],
[
[
1264,
63,
618
],
[
618,
24,
673
]
],
[
[
1264,
24,
823
],
[
823,
63,
673
]
],
[
[
1264,
25,
1039
],
[
1039,
24,
673
]
]
] | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"ADRA1B"
],
[
"ADRA1B",
"{u} (Gene) is bound by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
]
] | Doxepin may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Doxepin may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Doxepin (Compound) binds ADRA1B (Gene) and ADRA1B (Gene) is bound by Aripiprazole (Compound)
Doxepin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Aripiprazole (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Aripiprazole
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Doxepin may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole |
DB06723 | DB08931 | 115 | 947 | [
"DDInter58",
"DDInter1600"
] | Aluminum hydroxide | Riociguat | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. | Moderate | 1 | [
[
[
115,
24,
947
]
],
[
[
115,
62,
1220
],
[
1220,
24,
947
]
],
[
[
115,
63,
478
],
[
478,
24,
947
]
],
[
[
115,
25,
1475
],
[
1475,
63,
947
]
],
[
[
115,
62,
1220
],
[
1220,
24,
1478
],
[
1478,
24,
947
]
],
[
[
115,
63,
478
],
[
478,
63,
379
],
[
379,
24,
947
]
],
[
[
115,
63,
1195
],
[
1195,
25,
379
],
[
379,
24,
947
]
],
[
[
115,
21,
28882
],
[
28882,
60,
379
],
[
379,
24,
947
]
],
[
[
115,
25,
1475
],
[
1475,
63,
478
],
[
478,
24,
947
]
],
[
[
115,
62,
1220
],
[
1220,
63,
609
],
[
609,
24,
947
]
]
] | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
]
] | Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may lead to a major life threatening interaction when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Riociguat |
DB00319 | DB01172 | 790 | 416 | [
"DDInter1474",
"DDInter1004"
] | Piperacillin | Kanamycin | Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
790,
24,
416
]
],
[
[
790,
21,
28680
],
[
28680,
60,
416
]
],
[
[
790,
40,
1390
],
[
1390,
63,
416
]
],
[
[
790,
24,
1662
],
[
1662,
63,
416
]
],
[
[
790,
25,
663
],
[
663,
24,
416
]
],
[
[
790,
1,
1458
],
[
1458,
63,
416
]
],
[
[
790,
1,
1681
],
[
1681,
24,
416
]
],
[
[
790,
24,
1096
],
[
1096,
24,
416
]
],
[
[
790,
24,
1448
],
[
1448,
35,
416
]
],
[
[
790,
21,
28680
],
[
28680,
60,
138
],
[
138,
1,
416
]
]
] | [
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Ticarcillin"
],
[
"Ticarcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoperazone"
],
[
"Cefoperazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Mezlocillin"
],
[
"Mezlocillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piperacillin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tobramycin"
],
[
"Tobramycin",
"{u} (Compound) resembles {v} (Compound)",
"Kanamycin"
]
]
] | Piperacillin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Kanamycin (Compound)
Piperacillin (Compound) resembles Ticarcillin (Compound) and Ticarcillin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin (Compound) resembles Cefoperazone (Compound) and Cefoperazone may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin (Compound) resembles Mezlocillin (Compound) and Mezlocillin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piperacillin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound) |
DB00353 | DB11730 | 588 | 351 | [
"DDInter1187",
"DDInter1588"
] | Methylergometrine | Ribociclib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
588,
24,
351
]
],
[
[
588,
24,
283
],
[
283,
62,
351
]
],
[
[
588,
24,
597
],
[
597,
24,
351
]
],
[
[
588,
40,
628
],
[
628,
24,
351
]
],
[
[
588,
63,
1324
],
[
1324,
24,
351
]
],
[
[
588,
1,
469
],
[
469,
24,
351
]
],
[
[
588,
24,
1017
],
[
1017,
63,
351
]
],
[
[
588,
24,
129
],
[
129,
25,
351
]
],
[
[
588,
24,
1297
],
[
1297,
64,
351
]
],
[
[
588,
25,
609
],
[
609,
25,
351
]
]
] | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
],
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Methylergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Methylergometrine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Methylergometrine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Methylergometrine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ribociclib |
DB00420 | DB00938 | 508 | 455 | [
"DDInter1532",
"DDInter1635"
] | Promazine | Salmeterol | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
508,
24,
455
]
],
[
[
508,
24,
688
],
[
688,
63,
455
]
],
[
[
508,
6,
8374
],
[
8374,
45,
455
]
],
[
[
508,
7,
1986
],
[
1986,
46,
455
]
],
[
[
508,
18,
3965
],
[
3965,
57,
455
]
],
[
[
508,
24,
167
],
[
167,
23,
455
]
],
[
[
508,
24,
1042
],
[
1042,
62,
455
]
],
[
[
508,
25,
1593
],
[
1593,
63,
455
]
],
[
[
508,
24,
1144
],
[
1144,
24,
455
]
],
[
[
508,
1,
1237
],
[
1237,
63,
455
]
]
] | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} (Compound) downregulates {v} (Gene)",
"MRPS2"
],
[
"MRPS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
]
] | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Promazine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Salmeterol (Compound)
Promazine (Compound) downregulates MRPS2 (Gene) and MRPS2 (Gene) is downregulated by Salmeterol (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Promazine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Promazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB00334 | DB00350 | 867 | 1,214 | [
"DDInter1326",
"DDInter1226"
] | Olanzapine | Minoxidil | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Moderate | 1 | [
[
[
867,
24,
1214
]
],
[
[
867,
24,
530
],
[
530,
63,
1214
]
],
[
[
867,
25,
593
],
[
593,
63,
1214
]
],
[
[
867,
64,
475
],
[
475,
24,
1214
]
],
[
[
867,
40,
1408
],
[
1408,
63,
1214
]
],
[
[
867,
1,
623
],
[
623,
63,
1214
]
],
[
[
867,
24,
530
],
[
530,
6,
10522
],
[
10522,
45,
1214
]
],
[
[
867,
25,
593
],
[
593,
25,
924
],
[
924,
63,
1214
]
],
[
[
867,
24,
407
],
[
407,
63,
614
],
[
614,
63,
1214
]
],
[
[
867,
24,
104
],
[
104,
24,
1655
],
[
1655,
63,
1214
]
]
] | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Loxapine"
],
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
],
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
]
] | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Minoxidil (Compound)
Olanzapine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine and Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc and Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil |
DB00563 | DB00999 | 663 | 504 | [
"DDInter1174",
"DDInter883"
] | Methotrexate | Hydrochlorothiazide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959. | Moderate | 1 | [
[
[
663,
24,
504
]
],
[
[
663,
24,
178
],
[
178,
1,
504
]
],
[
[
663,
63,
323
],
[
323,
40,
504
]
],
[
[
663,
24,
359
],
[
359,
40,
504
]
],
[
[
663,
6,
10612
],
[
10612,
45,
504
]
],
[
[
663,
18,
4729
],
[
4729,
57,
504
]
],
[
[
663,
21,
29561
],
[
29561,
60,
504
]
],
[
[
663,
63,
964
],
[
964,
23,
504
]
],
[
[
663,
24,
1669
],
[
1669,
62,
504
]
],
[
[
663,
24,
1545
],
[
1545,
23,
504
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"EBNA1BP2"
],
[
"EBNA1BP2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Mood swings"
],
[
"Mood swings",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydrochlorothiazide (Compound)
Methotrexate (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Hydrochlorothiazide (Compound)
Methotrexate (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Hydrochlorothiazide (Compound)
Methotrexate (Compound) causes Mood swings (Side Effect) and Mood swings (Side Effect) is caused by Hydrochlorothiazide (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide |
DB00631 | DB05812 | 372 | 1,374 | [
"DDInter405",
"DDInter8"
] | Clofarabine | Abiraterone | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Moderate | 1 | [
[
[
372,
24,
1374
]
],
[
[
372,
63,
1561
],
[
1561,
1,
1374
]
],
[
[
372,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
372,
24,
1247
],
[
1247,
23,
1374
]
],
[
[
372,
24,
68
],
[
68,
62,
1374
]
],
[
[
372,
24,
1399
],
[
1399,
63,
1374
]
],
[
[
372,
63,
109
],
[
109,
24,
1374
]
],
[
[
372,
24,
876
],
[
876,
24,
1374
]
],
[
[
372,
25,
676
],
[
676,
63,
1374
]
],
[
[
372,
1,
1585
],
[
1585,
24,
1374
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Adenosine"
],
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
]
] | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Clofarabine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Clofarabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Clofarabine (Compound) resembles Adenosine (Compound) and Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone |
DB00880 | DB00983 | 359 | 480 | [
"DDInter360",
"DDInter776"
] | Chlorothiazide | Formoterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989] | Moderate | 1 | [
[
[
359,
24,
480
]
],
[
[
359,
21,
28762
],
[
28762,
60,
480
]
],
[
[
359,
63,
218
],
[
218,
23,
480
]
],
[
[
359,
24,
1042
],
[
1042,
62,
480
]
],
[
[
359,
24,
1486
],
[
1486,
23,
480
]
],
[
[
359,
24,
1053
],
[
1053,
63,
480
]
],
[
[
359,
25,
57
],
[
57,
63,
480
]
],
[
[
359,
63,
1674
],
[
1674,
24,
480
]
],
[
[
359,
24,
455
],
[
455,
24,
480
]
],
[
[
359,
40,
1326
],
[
1326,
63,
480
]
]
] | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
]
] | Chlorothiazide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Formoterol (Compound)
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Beclomethasone dipropionate and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Formoterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Formoterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Formoterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Chlorothiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Chlorothiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol |
DB00590 | DB01041 | 1,433 | 770 | [
"DDInter592",
"DDInter1789"
] | Doxazosin | Thalidomide | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
1433,
24,
770
]
],
[
[
1433,
6,
10215
],
[
10215,
45,
770
]
],
[
[
1433,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1433,
24,
609
],
[
609,
63,
770
]
],
[
[
1433,
63,
1614
],
[
1614,
24,
770
]
],
[
[
1433,
24,
104
],
[
104,
24,
770
]
],
[
[
1433,
40,
479
],
[
479,
24,
770
]
],
[
[
1433,
1,
1205
],
[
1205,
24,
770
]
],
[
[
1433,
40,
195
],
[
195,
63,
770
]
],
[
[
1433,
24,
167
],
[
167,
25,
770
]
]
] | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Terazosin"
],
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
]
] | Doxazosin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Doxazosin (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin (Compound) resembles Donepezil (Compound) and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin (Compound) resembles Terazosin (Compound) and Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide |
DB00465 | DB01088 | 886 | 714 | [
"DDInter1010",
"DDInter908"
] | Ketorolac | Iloprost | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
886,
24,
714
]
],
[
[
886,
25,
1479
],
[
1479,
24,
714
]
],
[
[
886,
63,
1432
],
[
1432,
24,
714
]
],
[
[
886,
24,
1226
],
[
1226,
24,
714
]
],
[
[
886,
1,
24
],
[
24,
24,
714
]
],
[
[
886,
24,
1564
],
[
1564,
63,
714
]
],
[
[
886,
25,
840
],
[
840,
63,
714
]
],
[
[
886,
25,
1421
],
[
1421,
64,
714
]
],
[
[
886,
76,
1172
],
[
1172,
25,
714
]
],
[
[
886,
25,
553
],
[
553,
25,
714
]
]
] | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} (Compound) resembles {v} (Compound)",
"Tolmetin"
],
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
]
]
] | Ketorolac may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Ketorolac may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan and Ketorolac may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Iloprost
Ketorolac may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Iloprost |
DB00668 | DB00777 | 874 | 146 | [
"DDInter652",
"DDInter1537"
] | Epinephrine | Propiomazine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades,,. On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | Moderate | 1 | [
[
[
874,
24,
146
]
],
[
[
874,
63,
508
],
[
508,
1,
146
]
],
[
[
874,
24,
401
],
[
401,
63,
146
]
],
[
[
874,
24,
1178
],
[
1178,
1,
146
]
],
[
[
874,
25,
1237
],
[
1237,
1,
146
]
],
[
[
874,
24,
104
],
[
104,
40,
146
]
],
[
[
874,
6,
5214
],
[
5214,
45,
146
]
],
[
[
874,
63,
176
],
[
176,
24,
146
]
],
[
[
874,
25,
1264
],
[
1264,
63,
146
]
],
[
[
874,
24,
1144
],
[
1144,
24,
146
]
]
] | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
]
] | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Propiomazine (Compound)
Epinephrine may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Propiomazine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Propiomazine (Compound)
Epinephrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Propiomazine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Epinephrine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine |
DB00358 | DB09054 | 1,010 | 384 | [
"DDInter1140",
"DDInter905"
] | Mefloquine | Idelalisib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
1010,
24,
384
]
],
[
[
1010,
25,
318
],
[
318,
23,
384
]
],
[
[
1010,
64,
1230
],
[
1230,
23,
384
]
],
[
[
1010,
24,
1627
],
[
1627,
62,
384
]
],
[
[
1010,
24,
555
],
[
555,
23,
384
]
],
[
[
1010,
25,
1618
],
[
1618,
24,
384
]
],
[
[
1010,
24,
1565
],
[
1565,
24,
384
]
],
[
[
1010,
63,
1570
],
[
1570,
24,
384
]
],
[
[
1010,
24,
1228
],
[
1228,
63,
384
]
],
[
[
1010,
64,
228
],
[
228,
24,
384
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] | Mefloquine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefloquine may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Mefloquine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Mefloquine may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB00945 | DB01320 | 1,479 | 651 | [
"DDInter20",
"DDInter783"
] | Acetylsalicylic acid | Fosphenytoin | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others. Acetylsalicylic acid is a very common | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Minor | 0 | [
[
[
1479,
23,
651
]
],
[
[
1479,
62,
362
],
[
362,
1,
651
]
],
[
[
1479,
63,
998
],
[
998,
1,
651
]
],
[
[
1479,
6,
6017
],
[
6017,
45,
651
]
],
[
[
1479,
21,
28856
],
[
28856,
60,
651
]
],
[
[
1479,
63,
1347
],
[
1347,
23,
651
]
],
[
[
1479,
63,
590
],
[
590,
24,
651
]
],
[
[
1479,
25,
1468
],
[
1468,
63,
651
]
],
[
[
1479,
24,
877
],
[
877,
63,
651
]
],
[
[
1479,
23,
1311
],
[
1311,
24,
651
]
]
] | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Acidosis"
],
[
"Acidosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
]
] | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Fosphenytoin (Compound)
Acetylsalicylic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Acetylsalicylic acid (Compound) causes Acidosis (Side Effect) and Acidosis (Side Effect) is caused by Fosphenytoin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin |
DB00015 | DB06605 | 582 | 1,409 | [
"DDInter1585",
"DDInter108"
] | Reteplase | Apixaban | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
582,
25,
1409
]
],
[
[
582,
23,
539
],
[
539,
62,
1409
]
],
[
[
582,
24,
109
],
[
109,
24,
1409
]
],
[
[
582,
24,
41
],
[
41,
63,
1409
]
],
[
[
582,
25,
235
],
[
235,
64,
1409
]
],
[
[
582,
24,
24
],
[
24,
25,
1409
]
],
[
[
582,
25,
39
],
[
39,
25,
1409
]
],
[
[
582,
64,
942
],
[
942,
25,
1409
]
],
[
[
582,
24,
578
],
[
578,
64,
1409
]
],
[
[
582,
23,
539
],
[
539,
62,
802
],
[
802,
64,
1409
]
]
] | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
]
] | Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Reteplase may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Apixaban
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin may lead to a major life threatening interaction when taken with Apixaban
Reteplase may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Apixaban
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Apixaban
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Apixaban
Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Apixaban |
DB01234 | DB08893 | 1,220 | 271 | [
"DDInter513",
"DDInter1229"
] | Dexamethasone | Mirabegron | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan. | Minor | 0 | [
[
[
1220,
23,
271
]
],
[
[
1220,
63,
1523
],
[
1523,
40,
271
]
],
[
[
1220,
6,
6648
],
[
6648,
45,
271
]
],
[
[
1220,
21,
29232
],
[
29232,
60,
271
]
],
[
[
1220,
24,
129
],
[
129,
62,
271
]
],
[
[
1220,
24,
392
],
[
392,
23,
271
]
],
[
[
1220,
25,
283
],
[
283,
62,
271
]
],
[
[
1220,
63,
723
],
[
723,
23,
271
]
],
[
[
1220,
25,
478
],
[
478,
23,
271
]
],
[
[
1220,
24,
214
],
[
214,
63,
271
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"SLCO1A2"
],
[
"SLCO1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
]
] | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Mirabegron (Compound)
Dexamethasone (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Mirabegron (Compound)
Dexamethasone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mirabegron (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexamethasone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexamethasone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron |
DB01149 | DB14723 | 851 | 159 | [
"DDInter1274",
"DDInter1026"
] | Nefazodone | Larotrectinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Major | 2 | [
[
[
851,
25,
159
]
],
[
[
851,
64,
222
],
[
222,
23,
159
]
],
[
[
851,
23,
466
],
[
466,
23,
159
]
],
[
[
851,
25,
1135
],
[
1135,
23,
159
]
],
[
[
851,
24,
98
],
[
98,
24,
159
]
],
[
[
851,
25,
951
],
[
951,
24,
159
]
],
[
[
851,
64,
1181
],
[
1181,
24,
159
]
],
[
[
851,
63,
322
],
[
322,
24,
159
]
],
[
[
851,
1,
623
],
[
623,
24,
159
]
],
[
[
851,
23,
1374
],
[
1374,
24,
159
]
]
] | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nefazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
]
] | Nefazodone may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nefazodone may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nefazodone may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nefazodone (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib |
DB00188 | DB01042 | 168 | 1,307 | [
"DDInter222",
"DDInter1144"
] | Bortezomib | Melphalan | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | Minor | 0 | [
[
[
168,
23,
1307
]
],
[
[
168,
24,
1191
],
[
1191,
1,
1307
]
],
[
[
168,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
168,
18,
3151
],
[
3151,
46,
1307
]
],
[
[
168,
7,
2969
],
[
2969,
46,
1307
]
],
[
[
168,
21,
28766
],
[
28766,
60,
1307
]
],
[
[
168,
24,
322
],
[
322,
23,
1307
]
],
[
[
168,
63,
66
],
[
66,
24,
1307
]
],
[
[
168,
24,
1186
],
[
1186,
63,
1307
]
],
[
[
168,
24,
869
],
[
869,
24,
1307
]
]
] | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"DDB2"
],
[
"DDB2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"CDKN1A"
],
[
"CDKN1A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
],
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
]
] | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Melphalan (Compound)
Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Bortezomib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound)
Bortezomib (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Melphalan (Compound)
Bortezomib (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Melphalan (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Melphalan |
DB00741 | DB00939 | 167 | 1,338 | [
"DDInter885",
"DDInter1135"
] | Hydrocortisone | Meclofenamic acid | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
167,
24,
1338
]
],
[
[
167,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
167,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
167,
1,
1573
],
[
1573,
24,
1338
]
],
[
[
167,
1,
1486
],
[
1486,
63,
1338
]
],
[
[
167,
63,
245
],
[
245,
24,
1338
]
],
[
[
167,
24,
473
],
[
473,
24,
1338
]
],
[
[
167,
25,
976
],
[
976,
63,
1338
]
],
[
[
167,
62,
1018
],
[
1018,
24,
1338
]
],
[
[
167,
64,
1314
],
[
1314,
24,
1338
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Meclofenamic acid (Compound)
Hydrocortisone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Hydrocortisone may lead to a major life threatening interaction when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid |
DB00333 | DB00434 | 576 | 13 | [
"DDInter1166",
"DDInter459"
] | Methadone | Cyproheptadine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric toxicity compared to other opioids (due to a lack of active metabolites), minimal accumulation in renal failure, good bioavailability, low cost, and a long duration of action.[F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
576,
24,
13
]
],
[
[
576,
24,
104
],
[
104,
63,
13
]
],
[
[
576,
21,
28905
],
[
28905,
60,
13
]
],
[
[
576,
63,
352
],
[
352,
24,
13
]
],
[
[
576,
1,
194
],
[
194,
63,
13
]
],
[
[
576,
36,
401
],
[
401,
63,
13
]
],
[
[
576,
35,
262
],
[
262,
63,
13
]
],
[
[
576,
24,
128
],
[
128,
24,
13
]
],
[
[
576,
35,
1594
],
[
1594,
24,
13
]
],
[
[
576,
25,
1053
],
[
1053,
63,
13
]
]
] | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Darifenacin"
],
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
]
] | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Cyproheptadine (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone (Compound) resembles Promethazine (Compound) and Methadone may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone (Compound) resembles Clidinium (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone (Compound) resembles Doxylamine (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Methadone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine |
DB00451 | DB14520 | 542 | 1,229 | [
"DDInter1064",
"DDInter1785"
] | Levothyroxine | Tetraferric tricitrate decahydrate | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or ), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.[F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
542,
24,
1229
]
],
[
[
542,
24,
954
],
[
954,
24,
1229
]
],
[
[
542,
40,
1152
],
[
1152,
24,
1229
]
],
[
[
542,
24,
954
],
[
954,
24,
1096
],
[
1096,
23,
1229
]
],
[
[
542,
24,
1436
],
[
1436,
63,
1152
],
[
1152,
24,
1229
]
],
[
[
542,
40,
1152
],
[
1152,
24,
1436
],
[
1436,
24,
1229
]
],
[
[
542,
6,
3486
],
[
3486,
45,
955
],
[
955,
23,
1229
]
],
[
[
542,
40,
624
],
[
624,
63,
1231
],
[
1231,
24,
1229
]
],
[
[
542,
24,
954
],
[
954,
24,
1669
],
[
1669,
24,
1229
]
],
[
[
542,
40,
1152
],
[
1152,
1,
1191
],
[
1191,
24,
1229
]
]
] | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
],
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
]
] | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Mycophenolate mofetil (Compound) and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Levothyroxine (Compound) resembles Liotrix (Compound) and Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Levothyroxine (Compound) resembles Liothyronine (Compound) and Liothyronine (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate |
DB00557 | DB11186 | 252 | 1,609 | [
"DDInter895",
"DDInter1427"
] | Hydroxyzine | Pentoxyverine | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
252,
24,
1609
]
],
[
[
252,
1,
623
],
[
623,
24,
1609
]
],
[
[
252,
24,
104
],
[
104,
24,
1609
]
],
[
[
252,
63,
999
],
[
999,
24,
1609
]
],
[
[
252,
74,
701
],
[
701,
24,
1609
]
],
[
[
252,
40,
827
],
[
827,
24,
1609
]
],
[
[
252,
64,
475
],
[
475,
24,
1609
]
],
[
[
252,
24,
1053
],
[
1053,
25,
1609
]
],
[
[
252,
1,
623
],
[
623,
40,
508
],
[
508,
24,
1609
]
],
[
[
252,
24,
104
],
[
104,
63,
314
],
[
314,
24,
1609
]
]
] | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
],
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
]
] | Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine (Compound) resembles Clemastine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine (Compound) resembles Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Pentoxyverine
Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00445 | DB08895 | 322 | 976 | [
"DDInter655",
"DDInter1825"
] | Epirubicin | Tofacitinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
322,
25,
976
]
],
[
[
322,
63,
1461
],
[
1461,
23,
976
]
],
[
[
322,
24,
214
],
[
214,
63,
976
]
],
[
[
322,
25,
982
],
[
982,
63,
976
]
],
[
[
322,
25,
868
],
[
868,
24,
976
]
],
[
[
322,
64,
494
],
[
494,
24,
976
]
],
[
[
322,
63,
534
],
[
534,
24,
976
]
],
[
[
322,
24,
1551
],
[
1551,
24,
976
]
],
[
[
322,
25,
1011
],
[
1011,
25,
976
]
],
[
[
322,
24,
1555
],
[
1555,
25,
976
]
]
] | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Epirubicin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Tofacitinib |
DB01229 | DB08899 | 973 | 129 | [
"DDInter1377",
"DDInter649"
] | Paclitaxel | Enzalutamide | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
973,
24,
129
]
],
[
[
973,
63,
918
],
[
918,
1,
129
]
],
[
[
973,
6,
8374
],
[
8374,
45,
129
]
],
[
[
973,
21,
29377
],
[
29377,
60,
129
]
],
[
[
973,
24,
110
],
[
110,
62,
129
]
],
[
[
973,
63,
112
],
[
112,
23,
129
]
],
[
[
973,
25,
1510
],
[
1510,
24,
129
]
],
[
[
973,
63,
851
],
[
851,
24,
129
]
],
[
[
973,
24,
1320
],
[
1320,
63,
129
]
],
[
[
973,
24,
1206
],
[
1206,
24,
129
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal pain"
],
[
"Musculoskeletal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
],
[
"Polatuzumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
"Gemfibrozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Paclitaxel (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Paclitaxel may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB06589 | DB08826 | 1,250 | 1,292 | [
"DDInter1400",
"DDInter489"
] | Pazopanib | Deferiprone | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Major | 2 | [
[
[
1250,
25,
1292
]
],
[
[
1250,
7,
6858
],
[
6858,
46,
1292
]
],
[
[
1250,
21,
28759
],
[
28759,
60,
1292
]
],
[
[
1250,
24,
1017
],
[
1017,
63,
1292
]
],
[
[
1250,
24,
115
],
[
115,
24,
1292
]
],
[
[
1250,
63,
1283
],
[
1283,
24,
1292
]
],
[
[
1250,
63,
482
],
[
482,
25,
1292
]
],
[
[
1250,
24,
1619
],
[
1619,
64,
1292
]
],
[
[
1250,
64,
57
],
[
57,
25,
1292
]
],
[
[
1250,
25,
351
],
[
351,
64,
1292
]
]
] | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"LPL"
],
[
"LPL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
]
] | Pazopanib (Compound) upregulates LPL (Gene) and LPL (Gene) is upregulated by Deferiprone (Compound)
Pazopanib (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Deferiprone
Pazopanib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Deferiprone
Pazopanib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Deferiprone |
DB06168 | DB10429 | 1,531 | 200 | [
"DDInter281",
"DDInter282"
] | Canakinumab | Candida albicans | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1531,
24,
200
]
],
[
[
1531,
63,
1096
],
[
1096,
24,
200
]
],
[
[
1531,
25,
976
],
[
976,
24,
200
]
],
[
[
1531,
24,
1019
],
[
1019,
63,
200
]
],
[
[
1531,
24,
1626
],
[
1626,
24,
200
]
],
[
[
1531,
64,
1377
],
[
1377,
24,
200
]
],
[
[
1531,
25,
1583
],
[
1583,
63,
200
]
],
[
[
1531,
63,
1096
],
[
1096,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1531,
63,
1683
],
[
1683,
63,
1096
],
[
1096,
24,
200
]
],
[
[
1531,
25,
976
],
[
976,
64,
1096
],
[
1096,
24,
200
]
]
] | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
],
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab and Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Canakinumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB00722 | DB00741 | 743 | 167 | [
"DDInter1079",
"DDInter885"
] | Lisinopril | Hydrocortisone | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
743,
24,
167
]
],
[
[
743,
24,
1220
],
[
1220,
40,
167
]
],
[
[
743,
63,
175
],
[
175,
40,
167
]
],
[
[
743,
63,
870
],
[
870,
1,
167
]
],
[
[
743,
6,
4973
],
[
4973,
45,
167
]
],
[
[
743,
21,
28642
],
[
28642,
60,
167
]
],
[
[
743,
23,
1384
],
[
1384,
62,
167
]
],
[
[
743,
24,
1254
],
[
1254,
63,
167
]
],
[
[
743,
23,
5
],
[
5,
63,
167
]
],
[
[
743,
63,
1179
],
[
1179,
24,
167
]
]
] | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
]
] | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Hydrocortisone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Lisinopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Hydrocortisone (Compound)
Lisinopril (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Hydrocortisone (Compound)
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone |
DB00630 | DB12015 | 1,485 | 1,033 | [
"DDInter42",
"DDInter53"
] | Alendronic acid | Alpelisib | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
1485,
24,
1033
]
],
[
[
1485,
1,
1199
],
[
1199,
24,
1033
]
],
[
[
1485,
40,
641
],
[
641,
24,
1033
]
],
[
[
1485,
63,
1512
],
[
1512,
24,
1033
]
],
[
[
1485,
24,
1274
],
[
1274,
24,
1033
]
],
[
[
1485,
1,
1199
],
[
1199,
25,
629
],
[
629,
24,
1033
]
],
[
[
1485,
40,
641
],
[
641,
25,
629
],
[
629,
24,
1033
]
],
[
[
1485,
1,
1008
],
[
1008,
40,
1199
],
[
1199,
24,
1033
]
],
[
[
1485,
63,
1512
],
[
1512,
24,
738
],
[
738,
24,
1033
]
],
[
[
1485,
24,
1274
],
[
1274,
24,
738
],
[
738,
24,
1033
]
]
] | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Pamidronic acid"
],
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Pamidronic acid"
],
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid (Compound) resembles Pamidronic acid (Compound) and Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid (Compound) resembles Pamidronic acid (Compound) and Pamidronic acid may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB01764 | DB11828 | 805 | 1,406 | [
"DDInter469",
"DDInter1281"
] | Dalfopristin | Neratinib | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
805,
25,
1406
]
],
[
[
805,
25,
1135
],
[
1135,
23,
1406
]
],
[
[
805,
63,
392
],
[
392,
24,
1406
]
],
[
[
805,
24,
1499
],
[
1499,
24,
1406
]
],
[
[
805,
25,
1456
],
[
1456,
24,
1406
]
],
[
[
805,
64,
1181
],
[
1181,
24,
1406
]
],
[
[
805,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
805,
24,
1593
],
[
1593,
25,
1406
]
],
[
[
805,
23,
283
],
[
283,
64,
1406
]
],
[
[
805,
63,
609
],
[
609,
25,
1406
]
]
] | [
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Dalfopristin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Dalfopristin may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Dalfopristin may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib |
DB00631 | DB01197 | 372 | 1,603 | [
"DDInter405",
"DDInter292"
] | Clofarabine | Captopril | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. | Moderate | 1 | [
[
[
372,
24,
1603
]
],
[
[
372,
63,
610
],
[
610,
1,
1603
]
],
[
[
372,
7,
1720
],
[
1720,
46,
1603
]
],
[
[
372,
7,
7647
],
[
7647,
57,
1603
]
],
[
[
372,
21,
28725
],
[
28725,
60,
1603
]
],
[
[
372,
63,
663
],
[
663,
24,
1603
]
],
[
[
372,
24,
267
],
[
267,
24,
1603
]
],
[
[
372,
24,
1613
],
[
1613,
63,
1603
]
],
[
[
372,
25,
1377
],
[
1377,
25,
1603
]
],
[
[
372,
25,
1510
],
[
1510,
64,
1603
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"RELB"
],
[
"RELB",
"{u} (Gene) is upregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"NPC1"
],
[
"NPC1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Captopril"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Captopril"
]
]
] | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Clofarabine (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Captopril (Compound)
Clofarabine (Compound) upregulates NPC1 (Gene) and NPC1 (Gene) is downregulated by Captopril (Compound)
Clofarabine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Captopril (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Captopril
Clofarabine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Captopril
Clofarabine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Captopril |
DB06589 | DB08912 | 1,250 | 1,040 | [
"DDInter1400",
"DDInter462"
] | Pazopanib | Dabrafenib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
1250,
24,
1040
]
],
[
[
1250,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1250,
18,
13128
],
[
13128,
46,
1040
]
],
[
[
1250,
6,
6732
],
[
6732,
46,
1040
]
],
[
[
1250,
7,
20044
],
[
20044,
46,
1040
]
],
[
[
1250,
7,
20113
],
[
20113,
57,
1040
]
],
[
[
1250,
18,
12821
],
[
12821,
57,
1040
]
],
[
[
1250,
6,
17136
],
[
17136,
57,
1040
]
],
[
[
1250,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1250,
24,
1612
],
[
1612,
62,
1040
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) downregulates {v} (Gene)",
"NARFL"
],
[
"NARFL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"MAP2K5"
],
[
"MAP2K5",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"METRN"
],
[
"METRN",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) upregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) downregulates {v} (Gene)",
"TRIB1"
],
[
"TRIB1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"SH2B3"
],
[
"SH2B3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
]
] | Pazopanib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Pazopanib (Compound) downregulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Pazopanib (Compound) binds MAP2K5 (Gene) and MAP2K5 (Gene) is upregulated by Dabrafenib (Compound)
Pazopanib (Compound) upregulates METRN (Gene) and METRN (Gene) is upregulated by Dabrafenib (Compound)
Pazopanib (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Dabrafenib (Compound)
Pazopanib (Compound) downregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Dabrafenib (Compound)
Pazopanib (Compound) binds SH2B3 (Gene) and SH2B3 (Gene) is downregulated by Dabrafenib (Compound)
Pazopanib (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Dabrafenib |
DB00842 | DB11130 | 686 | 407 | [
"DDInter1359",
"DDInter1344"
] | Oxazepam | Opium | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
686,
24,
407
]
],
[
[
686,
63,
662
],
[
662,
24,
407
]
],
[
[
686,
24,
104
],
[
104,
24,
407
]
],
[
[
686,
1,
1563
],
[
1563,
24,
407
]
],
[
[
686,
64,
475
],
[
475,
24,
407
]
],
[
[
686,
40,
1382
],
[
1382,
24,
407
]
],
[
[
686,
24,
1609
],
[
1609,
63,
407
]
],
[
[
686,
24,
593
],
[
593,
25,
407
]
],
[
[
686,
63,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
],
[
[
686,
24,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
]
] | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Opium
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00584 | DB09054 | 610 | 384 | [
"DDInter638",
"DDInter905"
] | Enalapril | Idelalisib | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
610,
24,
384
]
],
[
[
610,
63,
305
],
[
305,
24,
384
]
],
[
[
610,
24,
891
],
[
891,
24,
384
]
],
[
[
610,
40,
743
],
[
743,
24,
384
]
],
[
[
610,
1,
954
],
[
954,
24,
384
]
],
[
[
610,
24,
1613
],
[
1613,
63,
384
]
],
[
[
610,
24,
1486
],
[
1486,
25,
384
]
],
[
[
610,
25,
1510
],
[
1510,
25,
384
]
],
[
[
610,
24,
1019
],
[
1019,
64,
384
]
],
[
[
610,
63,
305
],
[
305,
24,
1627
],
[
1627,
62,
384
]
]
] | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
]
] | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Enalapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Enalapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Idelalisib
Enalapril may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Idelalisib
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib |
DB00586 | DB04868 | 1,512 | 478 | [
"DDInter537",
"DDInter1293"
] | Diclofenac | Nilotinib | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1512,
24,
478
]
],
[
[
1512,
25,
1468
],
[
1468,
63,
478
]
],
[
[
1512,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1512,
18,
5660
],
[
5660,
46,
478
]
],
[
[
1512,
6,
5066
],
[
5066,
46,
478
]
],
[
[
1512,
18,
2801
],
[
2801,
57,
478
]
],
[
[
1512,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1512,
23,
307
],
[
307,
23,
478
]
],
[
[
1512,
24,
1040
],
[
1040,
63,
478
]
],
[
[
1512,
23,
1559
],
[
1559,
24,
478
]
]
] | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) downregulates {v} (Gene)",
"TNIP1"
],
[
"TNIP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CXCL8"
],
[
"CXCL8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Diclofenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Diclofenac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Diclofenac (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Nilotinib (Compound)
Diclofenac (Compound) binds CXCL8 (Gene) and CXCL8 (Gene) is upregulated by Nilotinib (Compound)
Diclofenac (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Nilotinib (Compound)
Diclofenac (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00888 | DB11627 | 1,001 | 1,367 | [
"DDInter1133",
"DDInter860"
] | Mechlorethamine | Hepatitis B Vaccine (Recombinant) | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
1001,
24,
1367
]
],
[
[
1001,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1001,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1001,
24,
259
],
[
259,
24,
1367
]
],
[
[
1001,
25,
375
],
[
375,
24,
1367
]
],
[
[
1001,
40,
450
],
[
450,
24,
1367
]
],
[
[
1001,
24,
738
],
[
738,
63,
1367
]
],
[
[
1001,
25,
676
],
[
676,
63,
1367
]
],
[
[
1001,
63,
1648
],
[
1648,
24,
1560
],
[
1560,
24,
1367
]
],
[
[
1001,
64,
1064
],
[
1064,
36,
1083
],
[
1083,
24,
1367
]
]
] | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
]
] | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Mechlorethamine may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB00877 | DB01068 | 629 | 1,565 | [
"DDInter1678",
"DDInter411"
] | Sirolimus | Clonazepam | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse.[FDA Label][L5572,F3763,F3787,F3796] | Moderate | 1 | [
[
[
629,
24,
1565
]
],
[
[
629,
63,
1382
],
[
1382,
1,
1565
]
],
[
[
629,
63,
1216
],
[
1216,
40,
1565
]
],
[
[
629,
24,
1418
],
[
1418,
40,
1565
]
],
[
[
629,
6,
8374
],
[
8374,
45,
1565
]
],
[
[
629,
21,
29108
],
[
29108,
60,
1565
]
],
[
[
629,
63,
1031
],
[
1031,
23,
1565
]
],
[
[
629,
24,
259
],
[
259,
63,
1565
]
],
[
[
629,
63,
1101
],
[
1101,
24,
1565
]
],
[
[
629,
25,
384
],
[
384,
63,
1565
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Increased appetite"
],
[
"Increased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
]
] | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clonazepam (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Clonazepam (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Clonazepam (Compound)
Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonazepam (Compound)
Sirolimus (Compound) causes Increased appetite (Side Effect) and Increased appetite (Side Effect) is caused by Clonazepam (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Clonazepam
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Sirolimus may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam |
DB00231 | DB00692 | 1,174 | 274 | [
"DDInter1761",
"DDInter1448"
] | Temazepam | Phentolamine | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chemical synthesis of temazepam was established by 1965, mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on. In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to obtain the necessary rest required for medical recovery or scheduled maneuvers and operations. Regardless, temazepam has become one of the most frequently prescribed medications internationally and sees | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | Moderate | 1 | [
[
[
1174,
24,
274
]
],
[
[
1174,
21,
29118
],
[
29118,
60,
274
]
],
[
[
1174,
1,
695
],
[
695,
24,
274
]
],
[
[
1174,
24,
530
],
[
530,
24,
274
]
],
[
[
1174,
24,
104
],
[
104,
63,
274
]
],
[
[
1174,
1,
686
],
[
686,
63,
274
]
],
[
[
1174,
40,
1382
],
[
1382,
24,
274
]
],
[
[
1174,
25,
475
],
[
475,
24,
274
]
],
[
[
1174,
21,
29118
],
[
29118,
60,
530
],
[
530,
24,
274
]
],
[
[
1174,
21,
28658
],
[
28658,
60,
572
],
[
572,
63,
274
]
]
] | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Temazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fenoldopam"
],
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
]
] | Temazepam (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Temazepam (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Temazepam (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Fenoldopam (Compound) and Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine |
DB00213 | DB00774 | 837 | 1,577 | [
"DDInter1388",
"DDInter889"
] | Pantoprazole | Hydroflumethiazide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
837,
24,
1577
]
],
[
[
837,
24,
359
],
[
359,
40,
1577
]
],
[
[
837,
24,
504
],
[
504,
1,
1577
]
],
[
[
837,
21,
29455
],
[
29455,
60,
1577
]
],
[
[
837,
24,
126
],
[
126,
23,
1577
]
],
[
[
837,
1,
660
],
[
660,
24,
1577
]
],
[
[
837,
24,
1287
],
[
1287,
24,
1577
]
],
[
[
837,
1,
379
],
[
379,
63,
1577
]
],
[
[
837,
25,
663
],
[
663,
24,
1577
]
],
[
[
837,
24,
359
],
[
359,
40,
504
],
[
504,
1,
1577
]
]
] | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Agranulocytosis"
],
[
"Agranulocytosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
]
] | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Pantoprazole (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Hydroflumethiazide (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Pantoprazole may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound) |
DB00615 | DB04845 | 690 | 309 | [
"DDInter1589",
"DDInter1001"
] | Rifabutin | Ixabepilone | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Moderate | 1 | [
[
[
690,
24,
309
]
],
[
[
690,
6,
8374
],
[
8374,
45,
309
]
],
[
[
690,
21,
28725
],
[
28725,
60,
309
]
],
[
[
690,
25,
1419
],
[
1419,
24,
309
]
],
[
[
690,
24,
1619
],
[
1619,
63,
309
]
],
[
[
690,
25,
1593
],
[
1593,
63,
309
]
],
[
[
690,
24,
1487
],
[
1487,
24,
309
]
],
[
[
690,
63,
10
],
[
10,
24,
309
]
],
[
[
690,
40,
463
],
[
463,
24,
309
]
],
[
[
690,
23,
86
],
[
86,
24,
309
]
]
] | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
]
] | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Rifabutin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Ixabepilone (Compound)
Rifabutin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone |
DB06176 | DB11110 | 1,342 | 603 | [
"DDInter1616",
"DDInter1115"
] | Romidepsin | Magnesium citrate | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
1342,
24,
603
]
],
[
[
1342,
64,
57
],
[
57,
24,
603
]
],
[
[
1342,
63,
789
],
[
789,
24,
603
]
],
[
[
1342,
24,
1616
],
[
1616,
24,
603
]
],
[
[
1342,
24,
484
],
[
484,
63,
603
]
],
[
[
1342,
25,
1375
],
[
1375,
63,
603
]
],
[
[
1342,
25,
996
],
[
996,
24,
603
]
],
[
[
1342,
24,
241
],
[
241,
64,
603
]
],
[
[
1342,
64,
57
],
[
57,
64,
789
],
[
789,
24,
603
]
],
[
[
1342,
63,
789
],
[
789,
25,
57
],
[
57,
24,
603
]
]
] | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] | Romidepsin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Magnesium citrate
Romidepsin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB00987 | DB05273 | 1,224 | 507 | [
"DDInter460",
"DDInter1638"
] | Cytarabine | Samarium (153Sm) lexidronam | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
1224,
25,
507
]
],
[
[
1224,
24,
248
],
[
248,
24,
507
]
],
[
[
1224,
24,
270
],
[
270,
63,
507
]
],
[
[
1224,
64,
1101
],
[
1101,
25,
507
]
],
[
[
1224,
63,
970
],
[
970,
25,
507
]
],
[
[
1224,
24,
850
],
[
850,
64,
507
]
],
[
[
1224,
24,
77
],
[
77,
25,
507
]
],
[
[
1224,
76,
1064
],
[
1064,
25,
507
]
],
[
[
1224,
40,
1426
],
[
1426,
25,
507
]
],
[
[
1224,
25,
1259
],
[
1259,
64,
507
]
]
] | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound)",
"Azacitidine"
],
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Cytarabine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cytarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine (Compound) resembles Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Cytarabine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam |
DB01234 | DB10429 | 1,220 | 200 | [
"DDInter513",
"DDInter282"
] | Dexamethasone | Candida albicans | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1220,
24,
200
]
],
[
[
1220,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1220,
25,
976
],
[
976,
24,
200
]
],
[
[
1220,
62,
168
],
[
168,
24,
200
]
],
[
[
1220,
25,
1019
],
[
1019,
63,
200
]
],
[
[
1220,
1,
1486
],
[
1486,
24,
200
]
],
[
[
1220,
63,
613
],
[
613,
24,
200
]
],
[
[
1220,
24,
1316
],
[
1316,
63,
200
]
],
[
[
1220,
40,
1573
],
[
1573,
24,
200
]
],
[
[
1220,
64,
1377
],
[
1377,
24,
200
]
]
] | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
[
"Durvalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Dexamethasone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB00777 | DB01168 | 146 | 1,053 | [
"DDInter1537",
"DDInter1526"
] | Propiomazine | Procarbazine | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
146,
24,
1053
]
],
[
[
146,
40,
9
],
[
9,
63,
1053
]
],
[
[
146,
24,
100
],
[
100,
24,
1053
]
],
[
[
146,
1,
104
],
[
104,
24,
1053
]
],
[
[
146,
63,
1648
],
[
1648,
24,
1053
]
],
[
[
146,
25,
1311
],
[
1311,
63,
1053
]
],
[
[
146,
24,
103
],
[
103,
63,
1053
]
],
[
[
146,
40,
216
],
[
216,
24,
1053
]
],
[
[
146,
63,
73
],
[
73,
25,
1053
]
],
[
[
146,
24,
407
],
[
407,
64,
1053
]
]
] | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Methotrimeprazine"
],
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
],
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
]
] | Propiomazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine and Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Procarbazine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Procarbazine |
DB00549 | DB00631 | 522 | 372 | [
"DDInter1955",
"DDInter405"
] | Zafirlukast | Clofarabine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
522,
24,
372
]
],
[
[
522,
24,
1488
],
[
1488,
40,
372
]
],
[
[
522,
6,
17404
],
[
17404,
45,
372
]
],
[
[
522,
21,
28882
],
[
28882,
60,
372
]
],
[
[
522,
24,
595
],
[
595,
24,
372
]
],
[
[
522,
63,
1560
],
[
1560,
24,
372
]
],
[
[
522,
24,
1655
],
[
1655,
63,
372
]
],
[
[
522,
1,
165
],
[
165,
63,
372
]
],
[
[
522,
24,
908
],
[
908,
64,
372
]
],
[
[
522,
25,
990
],
[
990,
64,
372
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
],
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
],
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} (Compound) resembles {v} (Compound)",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
]
] | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles Clofarabine (Compound)
Zafirlukast (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound)
Zafirlukast (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Clofarabine (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide and Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc and Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Zafirlukast (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Clofarabine
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Clofarabine |
DB00022 | DB14783 | 268 | 287 | [
"DDInter1408",
"DDInter574"
] | Peginterferon alfa-2b | Diroximel fumarate | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
268,
24,
287
]
],
[
[
268,
25,
1101
],
[
1101,
24,
287
]
],
[
[
268,
24,
1560
],
[
1560,
24,
287
]
],
[
[
268,
23,
450
],
[
450,
24,
287
]
],
[
[
268,
63,
1451
],
[
1451,
24,
287
]
],
[
[
268,
25,
1510
],
[
1510,
25,
287
]
],
[
[
268,
24,
908
],
[
908,
25,
287
]
],
[
[
268,
25,
676
],
[
676,
64,
287
]
],
[
[
268,
63,
1057
],
[
1057,
25,
287
]
],
[
[
268,
25,
1101
],
[
1101,
64,
1560
],
[
1560,
24,
287
]
]
] | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Diroximel fumarate
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00690 | DB01259 | 1,216 | 392 | [
"DDInter762",
"DDInter1024"
] | Flurazepam | Lapatinib | A benzodiazepine derivative used mainly as a hypnotic. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Moderate | 1 | [
[
[
1216,
24,
392
]
],
[
[
1216,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1216,
21,
28852
],
[
28852,
60,
392
]
],
[
[
1216,
63,
1419
],
[
1419,
24,
392
]
],
[
[
1216,
24,
1264
],
[
1264,
24,
392
]
],
[
[
1216,
1,
1563
],
[
1563,
24,
392
]
],
[
[
1216,
24,
159
],
[
159,
63,
392
]
],
[
[
1216,
40,
1565
],
[
1565,
24,
392
]
],
[
[
1216,
23,
286
],
[
286,
63,
392
]
],
[
[
1216,
1,
481
],
[
481,
63,
392
]
]
] | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
]
] | Flurazepam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Flurazepam (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Flurazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib |
DB08885 | DB11988 | 363 | 270 | [
"DDInter33",
"DDInter1321"
] | Aflibercept | Ocrelizumab | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain.[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
363,
24,
270
]
],
[
[
363,
24,
713
],
[
713,
24,
270
]
],
[
[
363,
63,
259
],
[
259,
24,
270
]
],
[
[
363,
24,
287
],
[
287,
63,
270
]
],
[
[
363,
64,
507
],
[
507,
24,
270
]
],
[
[
363,
25,
962
],
[
962,
25,
270
]
],
[
[
363,
25,
676
],
[
676,
64,
270
]
],
[
[
363,
64,
1066
],
[
1066,
25,
270
]
],
[
[
363,
24,
713
],
[
713,
24,
1060
],
[
1060,
63,
270
]
],
[
[
363,
63,
259
],
[
259,
23,
1193
],
[
1193,
23,
270
]
]
] | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
]
] | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aflibercept may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aflibercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Ocrelizumab
Aflibercept may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Aflibercept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ocrelizumab
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab |
DB00927 | DB06176 | 1,559 | 1,342 | [
"DDInter712",
"DDInter1616"
] | Famotidine | Romidepsin | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1559,
24,
1342
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
1559,
62,
112
],
[
112,
23,
1342
]
],
[
[
1559,
24,
956
],
[
956,
24,
1342
]
],
[
[
1559,
63,
485
],
[
485,
24,
1342
]
],
[
[
1559,
24,
1616
],
[
1616,
63,
1342
]
],
[
[
1559,
25,
786
],
[
786,
63,
1342
]
],
[
[
1559,
64,
876
],
[
876,
24,
1342
]
],
[
[
1559,
23,
286
],
[
286,
63,
1342
]
],
[
[
1559,
25,
1213
],
[
1213,
24,
1342
]
]
] | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
]
] | Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may lead to a major life threatening interaction when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Famotidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin |
DB00877 | DB01072 | 629 | 915 | [
"DDInter1678",
"DDInter129"
] | Sirolimus | Atazanavir | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Major | 2 | [
[
[
629,
25,
915
]
],
[
[
629,
25,
1327
],
[
1327,
1,
915
]
],
[
[
629,
6,
4973
],
[
4973,
45,
915
]
],
[
[
629,
21,
28660
],
[
28660,
60,
915
]
],
[
[
629,
63,
1031
],
[
1031,
23,
915
]
],
[
[
629,
24,
5
],
[
5,
63,
915
]
],
[
[
629,
63,
1101
],
[
1101,
24,
915
]
],
[
[
629,
25,
129
],
[
129,
63,
915
]
],
[
[
629,
24,
473
],
[
473,
24,
915
]
],
[
[
629,
24,
1456
],
[
1456,
64,
915
]
]
] | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Pelvic pain"
],
[
"Pelvic pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
]
]
] | Sirolimus may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Sirolimus (Compound) causes Pelvic pain (Side Effect) and Pelvic pain (Side Effect) is caused by Atazanavir (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Sirolimus may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Atazanavir |
DB00501 | DB00594 | 752 | 863 | [
"DDInter380",
"DDInter68"
] | Cimetidine | Amiloride | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | Minor | 0 | [
[
[
752,
23,
863
]
],
[
[
752,
6,
10715
],
[
10715,
45,
863
]
],
[
[
752,
21,
28921
],
[
28921,
60,
863
]
],
[
[
752,
23,
593
],
[
593,
63,
863
]
],
[
[
752,
23,
1512
],
[
1512,
24,
863
]
],
[
[
752,
24,
1264
],
[
1264,
63,
863
]
],
[
[
752,
63,
1645
],
[
1645,
24,
863
]
],
[
[
752,
6,
10715
],
[
10715,
45,
1376
],
[
1376,
63,
863
]
],
[
[
752,
6,
9752
],
[
9752,
58,
11590
],
[
11590,
44,
863
]
],
[
[
752,
21,
28921
],
[
28921,
60,
319
],
[
319,
62,
863
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A1"
],
[
"SLC22A1",
"{u} (Gene) is bound by {v} (Compound)",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A1"
],
[
"SLC22A1",
"{u} (Gene) is bound by {v} (Compound)",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A4"
],
[
"SLC22A4",
"{u} (Gene) is upregulated by {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Amiloride"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxicillin"
],
[
"Amoxicillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
]
]
] | Cimetidine (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Amiloride (Compound)
Cimetidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Amiloride (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Cimetidine (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Cimetidine (Compound) binds SLC22A4 (Gene) and SLC22A4 (Gene) is upregulated by hypertension (Disease) and hypertension (Disease) is treated by Amiloride (Compound)
Cimetidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Amoxicillin (Compound) and Amoxicillin may cause a minor interaction that can limit clinical effects when taken with Amiloride |
DB00495 | DB01030 | 139 | 869 | [
"DDInter1961",
"DDInter1835"
] | Zidovudine | Topotecan | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
139,
24,
869
]
],
[
[
139,
24,
613
],
[
613,
24,
869
]
],
[
[
139,
6,
17404
],
[
17404,
45,
869
]
],
[
[
139,
6,
5441
],
[
5441,
46,
869
]
],
[
[
139,
21,
28921
],
[
28921,
60,
869
]
],
[
[
139,
24,
310
],
[
310,
63,
869
]
],
[
[
139,
63,
482
],
[
482,
24,
869
]
],
[
[
139,
64,
367
],
[
367,
24,
869
]
],
[
[
139,
74,
141
],
[
141,
24,
869
]
],
[
[
139,
64,
1057
],
[
1057,
25,
869
]
]
] | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"TERT"
],
[
"TERT",
"{u} (Gene) is upregulated by {v} (Compound)",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Zidovudine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
]
]
] | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Zidovudine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Topotecan (Compound)
Zidovudine (Compound) binds TERT (Gene) and TERT (Gene) is upregulated by Topotecan (Compound)
Zidovudine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Topotecan (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Zidovudine may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Zidovudine (Compound) resembles Floxuridine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Zidovudine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Topotecan |
DB00193 | DB00782 | 534 | 1,123 | [
"DDInter1841",
"DDInter1535"
] | Tramadol | Propantheline | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
534,
24,
1123
]
],
[
[
534,
6,
2720
],
[
2720,
45,
1123
]
],
[
[
534,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
534,
24,
537
],
[
537,
63,
1123
]
],
[
[
534,
25,
1425
],
[
1425,
24,
1123
]
],
[
[
534,
24,
1442
],
[
1442,
24,
1123
]
],
[
[
534,
25,
401
],
[
401,
63,
1123
]
],
[
[
534,
6,
2720
],
[
2720,
45,
11241
],
[
11241,
1,
1123
]
],
[
[
534,
21,
28898
],
[
28898,
60,
359
],
[
359,
62,
1123
]
],
[
[
534,
21,
29759
],
[
29759,
60,
474
],
[
474,
23,
1123
]
]
] | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Isopropamide"
],
[
"Isopropamide",
"{u} (Compound) resembles {v} (Compound)",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary hesitation"
],
[
"Urinary hesitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acetaminophen"
],
[
"Acetaminophen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
]
] | Tramadol (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Propantheline (Compound)
Tramadol (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tramadol may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tramadol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tramadol (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Isopropamide (Compound) and Isopropamide (Compound) resembles Propantheline (Compound)
Tramadol (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline
Tramadol (Compound) causes Urinary hesitation (Side Effect) and Urinary hesitation (Side Effect) is caused by Acetaminophen (Compound) and Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Propantheline |
DB00381 | DB00641 | 376 | 467 | [
"DDInter79",
"DDInter1675"
] | Amlodipine | Simvastatin | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label]. | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as [pravastatin] and [rosuvastatin] which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.[A181424,A181460] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins. | Major | 2 | [
[
[
376,
25,
467
]
],
[
[
376,
10,
11576
],
[
11576,
44,
467
]
],
[
[
376,
6,
8374
],
[
8374,
45,
467
]
],
[
[
376,
7,
4634
],
[
4634,
46,
467
]
],
[
[
376,
18,
3023
],
[
3023,
57,
467
]
],
[
[
376,
7,
8839
],
[
8839,
57,
467
]
],
[
[
376,
21,
28810
],
[
28810,
60,
467
]
],
[
[
376,
24,
549
],
[
549,
62,
467
]
],
[
[
376,
40,
1428
],
[
1428,
23,
467
]
],
[
[
376,
63,
1101
],
[
1101,
24,
467
]
]
] | [
[
[
"Amlodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) palliates {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) upregulates {v} (Gene)",
"FOXO4"
],
[
"FOXO4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) downregulates {v} (Gene)",
"RUVBL1"
],
[
"RUVBL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) upregulates {v} (Gene)",
"GNPDA1"
],
[
"GNPDA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
]
] | Amlodipine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Simvastatin (Compound)
Amlodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound)
Amlodipine (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Simvastatin (Compound)
Amlodipine (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Simvastatin (Compound)
Amlodipine (Compound) upregulates GNPDA1 (Gene) and GNPDA1 (Gene) is downregulated by Simvastatin (Compound)
Amlodipine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Simvastatin (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Amlodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin |
DB00912 | DB01404 | 473 | 757 | [
"DDInter1581",
"DDInter820"
] | Repaglinide | Ginseng | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
473,
24,
757
]
],
[
[
473,
24,
170
],
[
170,
24,
757
]
],
[
[
473,
24,
1344
],
[
1344,
63,
757
]
],
[
[
473,
64,
1347
],
[
1347,
24,
757
]
],
[
[
473,
63,
1645
],
[
1645,
24,
757
]
],
[
[
473,
63,
1419
],
[
1419,
25,
757
]
],
[
[
473,
24,
170
],
[
170,
63,
245
],
[
245,
24,
757
]
],
[
[
473,
64,
1347
],
[
1347,
62,
245
],
[
245,
24,
757
]
],
[
[
473,
24,
1130
],
[
1130,
64,
1347
],
[
1347,
24,
757
]
],
[
[
473,
63,
1645
],
[
1645,
63,
245
],
[
245,
24,
757
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
]
] | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.